 | Back pain can restrict activity and quality of everyday life and in some cases is a potentially chronic and even crippling condition. Therefore, back pain exerts a large economic impact on society. Due to the high prevalence of back pain, Datamonitor believes that the condition represents a commercially attractive target to pharmaceutical companies with an interest in the pain market.Back pain overview including definition, risk factors, epidemiology and discussion of key unmet needs.Summary of the drug classes currently used for the treatment of back pain and an update of the latest treatment guidelines.Evaluation of three potentially viable market entry points to access the highly prevalent back pain population.Stakeholder opinions based on qualitative interviews with seven US and European key opinion leaders in the field of back pain.Despite the high prevalence of back pain, no marketed pharmacological product possesses an indication for this condition. The strategy has the potential to confer several commercial advantages, not least product differentiation. However, important clinical and regulatory hurdles lie in the path to successful implementation of this approach.
The plethora of inexpensive generic analgesics represents a sizable barrier to pharmaceutical companies hoping to either penetrate or increase their market share in the back pain sector. Targeting the narrowly defined chronic neuropathic back pain population represents one path to success for manufacturers of non-traditional analgesics.
Sales of oral products dominate the pain market and only a handful major topical patch brands are currently available. Given the conceptual benefit of applying treatment to the site of pain, marketing further patch formulations towards back pain is could be commercially viable strategy for drug delivery companies.Understand the prevalence of acute and chronic back pain, including the proportion of chronic back pain attributable to neuropathic mechanisms.Identify the key clinical unmet needs in the treatment of back pain as gauged by the insight provided by interviewed key opinion leaders.Evaluate the potential of three strategies which companies can employ in order to increase their presence in the back pain sector of the pain market. |
|
| This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Biogen Idec's performance against key rivals in the prescription pharmaceutical sectorSee how the company's sales will be driven by two key monoclonal antibody products: Rituxan and TysabriEvaluate Avonex's prospects as Biogen Idec's blockbuster multiple sclerosis product comes under increased pressure as Tysabri's sales continue to rise |
|
| Datamonitor's Pharmaceuticals: Extended Global Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis. Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards
* Covers the Global, European and Asia-Pacific markets as well as individual chapters on Australia, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Norway, Poland, Russia, Singapore, South Africa, South Korea, Spain, Sweden, United Kingdom and United States.
* Includes a five-year forecast of the industry Highlights The global pharmaceuticals market grew by 3.8% in 2008 to reach a value of $615.1 billion. In 2013 the market is forecast to have a value of $734 billion, an increase of 19.3% since 2008. The sale of cardiovascular pharmaceuticals accounts for 19.8% of the market. The Americans market of pharmaceuticals accounts for 51.9% of the market’s value. Pfizer is a leading company in market with 7.2% of the market’s value. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research Market Definition The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). |
|
| Datamonitor's OTC Pharmaceuticals: Extended Global Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis. Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards
* Covers the Global, European and Asia-Pacific markets as well as individual chapters on Australia, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Norway, Poland, Russia, Singapore, South Africa, South Korea, Spain, Sweden, United Kingdom and United States.
* Includes a five-year forecast of the industry Highlights The global OTC pharmaceuticals market grew by 3.9% in 2008 to reach a value of $104.2 billion. In 2013, the market is forecast to have a value of $124 billion, an increase of 19% since 2008. Sales of traditional medicines account for 20.3% of the global OTC pharmaceutical market's overall value. The Asia-Pacific accounts for 38.2% of the global OTC pharmaceutical market's value. Pfizer generates the largest share of the global OTC pharmacetuical market's value, accounting for a 6.1% Pharmacies and drug stores distribute 57.8% of the value in the global OTC pharmaceutical market. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research Market Definition The OTC pharmaceuticals market values the total sales of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin, other analgesics), and other OTC healthcare products including; medicated skin products (anti-bacterials, acne treatments, anti-fungals, other medicated skin products, disinfectants), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, other tape or bandage, liquid bandages), first aid kits and other OTC healthcare products (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, motion sickness). |
|
| BPH is a chronic urological condition involving the non-cancerous enlargement of the prostate affecting over 15 million men across the seven major markets. The market for BPH drugs that aim to alleviate the symptoms and reduce prostate size was worth $3.7bn in 2008. The BPH market is expected to continue growing over the next 10 years driven by the launch of new improved treatments.Analysis of BPH etiology, symptomology, diagnosis, treatment, current and future prevalence, and the key unmet market needs.Review of the complete pre-clinical and clinical pipeline for new BPH therapies, including analysis of key R&D company strategies.In depth analysis of historic (200408) and future (20092018) market dynamics, including profiles of Flomax and Avodart (dutasteride).Commercial and clinical assessment of key late-stage pipeline drugs, with opinion leader comment and region-specific sales forecasts to 2018.Generic market share is predicted to grow substantially by 2018 and prospective players in the symptomatic relief drug class in particular can expect tough competition. Commercial and clinical differentiation is key for a new drug's success and GlaxoSmithKline's Duodart (tamsulosin + dutasteride) appears well placed to achieve this.
BPH is an indication expansion opportunity for drugs approved for prostate cancer. In addition, there seems to be a general R&D effort to find therapies that will substitute the need of BPH related surgery. One such example is the development of intraprostatic injections that provide local prostate tissue loss while minimizing systemic effects.
Drugs with novel mechanisms of action, such as Nymox's NX-1207 (intraprostatic injection), are commercially attractive, demanding a price premium over current treatments. By offering alternative treatment to patients with severe BPH who would otherwise have undergone surgery, NX-1207 has potential to grow the market, although safety is a concern.Analyze competitive environment at time of product launch.Validate internal forecasts and market potential for pipeline products.Identify licensing opportunities based on company portfolio and market needs. |
|
| There are 224 different pipeline products in clinical development for hematological malignancies. Twenty-three (10%) of these drugs are in late-phase studies and are forecast to achieve peak sales of $3.5 billion in 2018. Drug developers are keen to replicate the success of the two blockbusters: Biogen Idec/Genentech/Roche's Rituxan (rituximab) and Novartis's Gleevec (imatinib).Epidemiology of the hematological malignancies split by disease subtype, covering the seven major markets as well as the top 5 rest of world marketsOverview of the current treatment options for leukemia, lymphoma, multiple myeloma and myelodysplastic syndromes with identification of unmet needsExamination of the late-phase hematological malignancies pipeline, key company market strategies and opportunities for drug developersPipeline insight based on qualitative interviews with key opinion leaders in the field of hematological malignanciesThere are 13 molecular-targeted therapies, six immunotherapeutic agents and four cytotoxic agents in late-phase clinical development for hematological malignancies. Immunotherapeutic agents are forecast to achieve the highest class sales of $1.7 billion in the seven major markets by 2018.
Pipeline agents holding the greatest commercial potential include the immunoconjugated monoclonal antibodies Arzerra (ofatumumab; Genmab/GlaxoSmithKline), galiximab (Biogen Idec) and lumiliximab (Biogen Idec), as well as the cytotoxic agent pixantrone (Novartis).
Smaller, niche indications are increasingly attracting R&D interest as a result of the high unmet needs that persist in a number of hematological malignancy subtypes. At least 9 (39%) of the 23 late-phase pipeline agents are targeting patient sub-populations to potentially fill gaps in the market and facilitate launch.Acquire a detailed appreciation and impartial perspective of the entire hematological malignancies developmental pipelineIdentify the key products in late-phase development based on sales forecasts to 2018 and Datamonitor's drug assessment methodologyAssess how the future treatment of many hematological malignancies will incorporate pipeline products |
|
| The diagnosis of renal anemia is routinely performed and relatively straightforward, while treatment with highly effective erythropoietin-stimulating agents is widely available in all major markets. However, the extremely high cost of treatment prevents many healthcare providers from delivering this treatment to all eligible patients.What are the current definitions, pathophysiological stages and the classification of renal anemia?What are the currently available diagnostic methods, the issues and the unmet needs in diagnosis and early detection of renal anemia?What is the current state of pharmacological management, available treatment approaches in renal anemia, unmet needs and future trends?What are the current issues and the commercial landscape of renal anemia marketplace?In Europe, biogeneric epoetins were expected to address the cost issue, however, so far they have not been particularly well received. This seems to be mostly due to physician conservatism and the fear of poor generic drug quality with attendant higher risk of side effects. Only Germany has displayed any degree of enthusiasm for biogenerics.
A number of large clinical trials, such as CHOIR and CREATE, have demonstrated some controversial results with regards to the relative inefficiency of higher hemoglobin targets. This has encouraged healthcare providers to be conservative in the choice of epoetin therapy creating an additional barrier to epoetin revenue growth.
New epoetin drug therapies predominantly address the length of drug action, allowing for less frequent administration, but unfortunately they provide neither substantial superiority nor significant reduction of costs. In addition, a very small upcoming pipeline does not yet promise any advancement in the area of superiority or reduction of cost.Understand current definitions, diagnostic methods and treatment approaches in renal anemiaCurrent challenges and future opportunities in renal anemia managementDifferences, advantages and disadvantages of pharmacological disease management |
|
| Urinary tract infections (UTIs) include infections of the kidneys, ureters, and bladder. Escherichia coli is the major UTI pathogen, with emerging extended-spectrum beta-lactamase (ESBL)-producing strains proving particularly difficult to treat. Bacterial resistance to the most commonly used UTI drugs is growing, highlighting the unmet need and opportunity for novel therapies.Disease background, segmentation and epidemiology of UTIs in the US, Japan and five major European countriesOverview of unmet needs, current clinical practice, guidelines and adherenceDiscussion of trends in incidence of major pathogens and therapies as well as resistance ratesOutline of diagnosis, treatment and referral patternsUTIs are a major driver of ambulatory care utilization. US statistics point to more than 10 million visits to ambulatory care settings for UTIs per year. From 1995 to 2006, the incidence of cystitis and UTI in unspecified sites in the US increased by 10.7%.
Bacterial resistance is the most important factor affecting UTI treatment options and varies both nationally and locally. Resistance rates as low as 10% are deemed to be of concern with regards to efficacy of empiric therapy. Levels of resistance to some older drugs may reach 40-50% in some areas, rendering these drugs ineffective.
Two old drugs, nitrofurantoin and fosfomycin, have remarkably favorable resistance profiles and good efficacy for the treatment of cystitis, and therefore may provide highly useful future treatment options. Given these compounds' age, they are not widely prescribed, requiring physician education to improve familiarity and improve their uptake.Learn about the significance of UTIs as a an indication for antibacterial compoundsUnderstand and capitalize on clinical unmet needs in the market through new product development in therapy and diagnosisDiscover optimal ways to communicate with physicians by supporting efforts to address gaps in diagnosis, treatment and guideline adherence |
|
| Hematopoietic stem cell transplantation (HSCT) has evolved considerably over the past 50 years, driven by developments in stem cell sources, donor identification and conditioning regimens. Nowadays, it has a range of applications, including the treatment of certain hematologic malignancies. However, further research efforts are required to expand its use and improve patient outcomes.Usage data for HSCT and overview of the procedure in terms of stem cell donors, stem cell sources, and conditioning regimensDiscussion of the use of drug therapy in HSCT conditioning and in the management of complications, including current research and development trendsUnmet needs and research priorities in the field of HSCTStakeholder opinions based on qualitative interviews with key opinion leaders from the US and EUThe use of HSCT has been increasing in the past decades, driven by developments in stem cell sources and conditioning regimens. However, it seems to remain an underutilized treatment, with many patients being referred for a transplant only at advanced stages of disease, where cure is less likely.
The development of reduced-intensity conditioning (RIC) regimens is one of the major advances in the field of HSCT. Current research evaluating monoclonal antibodies and radioimmunotherapy may help increase the efficacy and specificity of conditioning therapy.
The effective management of graft-versus-host disease (GVHD) is an unmet need in the field of HSCT. The availability of better preclinical models, prognostic tools, and effective therapies are considered R&D priorities. Monoclonal antibodies may have a role in the treatment of GVHD but further research is required to investigate their potential.Obtain analysis of current HSCT usage data and trends in the use of stem cell donors, stem cell sources, and conditioning regimensObtain an overview of current drug use in HSCT conditioning and in the management of HSCT complications, including graft-versus-host diseaseIdentify unmet needs and research priorities in the field of HSCT |
|
| Datamonitor's Pharmaceuticals: United States Industry Guide is an essential resource for top-level data and analysis covering the United States Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The United States biotechnology market grew by 11.3% in 2007 to reach a value of $84,760 million. * The US generics market generated total revenues of $30.8 billion in 2007, representing a compound annual growth rate (CAGR) of 16.8% for the period spanning 2003-2007. * The United States OTC pharmaceuticals market generated total revenues of $25.5 billion in 2008, representing a compound annual growth rate (CAGR) of 3.4% for the period spanning 2004-2008. * The United States market generated total revenues of $273.9 billion in 2008, representing a compound annual growth rate (CAGR) of 3.7% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: United Kingdom Industry Guide is an essential resource for top-level data and analysis covering the United Kingdom Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The United Kingdom biotechnology market grew by 7.8% in 2007 to reach a value of $7,179 million. * The UK’s generics market generated total revenues of $5.6 billion in 2007, representing a compound annual growth rate (CAGR) of 13.1% for the period spanning 2003-2007. * The United Kingdom OTC pharmaceuticals market generated total revenues of $5.5 billion in 2008, representing a compound annual growth rate (CAGR) of 2.7% for the period spanning 2004-2008. * The UK pharmaceuticals market generated total revenues of $25.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: Spain Industry Guide is an essential resource for top-level data and analysis covering the Spain Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The Spanish biotechnology market grew by 7.1% in 2007 to reach a value of $7,341 million. * The Spanish generics market generated total revenues of $1.2 billion in 2007, representing a compound annual growth rate (CAGR) of 15.8% for the period spanning 2003-2007. * The Spanish OTC pharmaceuticals market generated total revenues of $1.9 billion in 2008, representing a compound annual growth rate (CAGR) of 3% for the period spanning 2004-2008. * The Spanish pharmaceutical market generated total revenues of $18 billion in 2008, representing a compound annual growth rate (CAGR) of 5.5% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: Netherlands Industry Guide is an essential resource for top-level data and analysis covering the Netherlands Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The Dutch biotechnology market grew by 8.2% in 2007 to reach a value of $316 million. * The Dutch generics market generated total revenues of $771 million in 2007, representing a compound annual growth rate (CAGR) of 32.2% for the period spanning 2003-2007. * The Dutch OTC pharmaceuticals market generated total revenues of $923.9 million in 2008, representing a compound annual growth rate (CAGR) of 3.3% for the period spanning 2004-2008. * The Dutch pharmaceutical market generated total revenues of $6.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4.2% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: Japan Industry Guide is an essential resource for top-level data and analysis covering the Japan Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The Japanese biotechnology market grew by 8.2% in 2007 to reach a value of $17,447 million. * The Japanese generics market generated total revenues of $5.3 billion in 2007, representing a compound annual growth rate (CAGR) of 6.3% for the period spanning 2003-2007. * The Japanese OTC pharmaceuticals market generated total revenues of $14.5 billion in 2008, representing a compound annual growth rate (CAGR) of 1.6% for the period spanning 2004-2008. * The Japanese pharmaceutical market generated total revenues of $65.3 billion in 2008, representing a compound annual growth rate (CAGR) of 2.4% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: Italy Industry Guide is an essential resource for top-level data and analysis covering the Italy Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The Italian biotechnology market grew by 3.2% in 2007 to reach a value of $5,514 million. * The Italian generics market generated total revenues of $623.3 million in 2007, representing a compound annual growth rate (CAGR) of 12.9% for the period spanning 2003-2007. * The Italian OTC pharmaceuticals market generated total revenues of $3.2 billion in 2008, representing a compound annual growth rate (CAGR) of 2.4% for the period spanning 2004-2008. * The Italian pharmaceutical market generated total revenues of $21.9 billion in 2008, representing a compound annual growth rate (CAGR) of 1.3% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the Global Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The global biotechnology market grew by 10.6% in 2007 to reach a value of $171,803 million. * The global generics market generated total revenues of $108.1 billion in 2007, representing a compound annual growth rate (CAGR) of 14.8% for the period spanning 2003-2007. * The global OTC pharmaceuticals market generated total revenues of $104.2 billion in 2008, representing a compound annual growth rate (CAGR) of 4% for the period spanning 2004-2008. * The global pharmaceutical market generated total revenues of $615.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: Germany Industry Guide is an essential resource for top-level data and analysis covering the Germany Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The German biotechnology market grew by 7.8% in 2007 to reach a value of $5,026 million. * The German generics market generated total revenues of $9.9 billion in 2007, representing a compound annual growth rate (CAGR) of 17% for the period spanning 2003-2007. * The German OTC pharmaceuticals market generated total revenues of $6.8 billion in 2008, representing a compound annual growth rate (CAGR) of 1.2% for the period spanning 2004-2008. * The German pharmaceutical market generated total revenues of $36.2 billion in 2008, representing a compound annual growth rate (CAGR) of 2.9% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: France Industry Guide is an essential resource for top-level data and analysis covering the France Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The French biotechnology market grew by 8.9% in 2007 to reach a value of $3,982 million. * The French generics market generated total revenues of $3 billion in 2007, representing a compound annual growth rate (CAGR) of 21.3% for the period spanning 2003-2007. * The French OTC pharmaceuticals market generated total revenues of $3.5 billion in 2008, representing a compound annual growth rate (CAGR) of 2.4% for the period spanning 2004-2008. * The French pharmaceutical market generated total revenues of $36.4 billion in 2008, representing a compound annual growth rate (CAGR) of 4.3% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: Europe Industry Guide is an essential resource for top-level data and analysis covering the Europe Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The European biotechnology market grew by 9.3% in 2007 to reach a value of $42,145 million. * The European generics market generated total revenues of $32 billion in 2007, representing a compound annual growth rate (CAGR) of 13.6% for the period spanning 2003-2007. * The European OTC pharmaceuticals market generated total revenues of $31.1 billion in 2008, representing a compound annual growth rate (CAGR) of 3.1% for the period spanning 2004-2008. * The European pharmaceutical market generated total revenues of $177.6 billion in 2008, representing a compound annual growth rate (CAGR) of 4.4% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: China Industry Guide is an essential resource for top-level data and analysis covering the China Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The Chinese biotechnology market grew by 24.9% in 2007 to reach a value of $5,565 million. * The Chinese generics market generated total revenues of $17.9 billion in 2007, representing a compound annual growth rate (CAGR) of 21.3% for the period spanning 2003-2007. * The Chinese OTC pharmaceuticals market generated total revenues of $16.1 billion in 2008, representing a compound annual growth rate (CAGR) of 7% for the period spanning 2004-2008. * The Chinese pharmaceutical market generated total revenues of $20.7 billion in 2008, representing a compound annual growth rate (CAGR) of 21.1% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: Canada Industry Guide is an essential resource for top-level data and analysis covering the Canada Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The Canadian biotechnology market grew by 5.0% in 2007 to reach a value of $4,321 million. * The Canadian generics market generated total revenues of $3.5 billion in 2007, representing a compound annual growth rate (CAGR) of 10.7% for the period spanning 2003-2007. * The Canadian OTC pharmaceuticals market generated total revenues of $2.3 billion in 2008, representing a compound annual growth rate (CAGR) of 3.5% for the period spanning 2004-2008. * Canadian pharmaceutical market generated total revenues of $24.2 billion in 2008, representing a compound annual growth rate (CAGR) of 6.6% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: Belgium Industry Guide is an essential resource for top-level data and analysis covering the Belgium Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The Belgian biotechnology market grew by 11.7% in 2007 to reach a value of $4,569.3 million. * The Belgian generics market generated total revenues of $420.7 million in 2007, representing a compound annual growth rate (CAGR) of 18% for the period spanning 2003-2007. * The Belgian OTC pharmaceuticals market generated total revenues of $816.8 million in 2008, representing a compound annual growth rate (CAGR) of 2.1% for the period spanning 2004-2008. * The Belgian pharmaceutical market generated total revenues of $6.1 billion in 2008, representing a compound annual growth rate (CAGR) of 5.6% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals: Asia-Pacific Industry Guide is an essential resource for top-level data and analysis covering the Asia-Pacific Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals Highlights * The Asia-Pacific biotechnology market grew by 11.6% in 2007 to reach a value of $37,316 million. * The Asia-Pacific generics market generated total revenues of $32.7 billion in 2007, representing a compound annual growth rate (CAGR) of 14% for the period spanning 2003-2007. * The Asia-Pacific OTC pharmaceuticals market generated total revenues of $39.8 billion in 2008, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2004-2008. * The Asia-Pacific pharmaceutical market generated total revenues of $118.3 billion in 2008, representing a compound annual growth rate (CAGR) of 6.6% for the period spanning 2004-2008. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| Datamonitor's Pharmaceuticals - Top 5 Emerging Markets Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the Top 5 Emerging markets (Brazil, China, India, Mexico and South Africa). The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market. Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards
* Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry Highlights The Top 5 Emerging countries contributed $46.4 billion to the global Pharmaceuticals industry in 2007, with a CAGR of 13.3% between 2004 and 2007 In 2013, the market is forecast to have a value of $100.5 billion, with a CAGR of 13.7% over the 2008–2013 period. China is the leading country among the Top 5 emerging nations, with market revenues of $16.7 billion in 2007. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research Market Definition The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). |
|
| Gastric cancer incidence in 2009 is forecast to be 197,000 in the seven major pharmaceutical markets (US, Japan, Germany, France, Italy, Spain, and UK). Although, the global incidence has decreased in recent years, mortality remains high, particularly in the US and Europe. Therefore, predictably a high unmet need remains for effective therapies to improve mortality.Gastric cancer overview, including definition, risk factors, epidemiology forecasts and discussion of unmet needsCurrent diagnosis and treatment of gastric cancer, including drug regimens used by stage and ongoing controversiesExamination of the late-phase gastric cancer pipeline and market opportunities for drug developersStakeholder opinions based on qualitative interviews with key opinion leaders in the field of gastric cancerSurgery is the mainstay of gastric cancer treatment. Chemotherapyalone or in combination with radiotherapyhas a role in the treatment of both early-stage and locoregional disease. However, its main application is in the treatment of advanced disease, where it is used with palliative intent and only results in a poor median survival of 79 months.
The Phase III gastric cancer pipeline comprises six drugs, five of which are molecular targeted therapies. All the drugs in the pipeline are intended for use in the first-line treatment of advanced gastric cancer.
The gastric cancer market is currently attracting R&D interest from key pharmaceutical players. Drugs such as Avastin (bevacizumab; Genentech/Roche/Chugai), Herceptin (trastuzumab; Genentech/Roche/Chugai), and Tykerb (lapatinib; GlaxoSmithKline) are seeking line extensions. Approval of any agents will result in a very competitive market.To estimate the number of treatable patients and understand where high unmet needs exist which may provide opportunity for pipeline agentsTo gain insight into the current dynamics of gastric cancer managementTo analyze the current gastric cancer pipeline drugs and understand effects of approval on market dynamics |
|
| Novel vaccine administration technologies have the potential to improve vaccine developers' commercial competitiveness and to increase vaccination safety and convenience. This report assesses key strategies, technologies and products for novel dermal and mucosal vaccine administration. It also provides an overview of opportunities and challenges for the sector and a future outlook.In-depth analysis of key dermal and mucosal vaccine administration technologiesThorough assessment of the potential for selected vaccine administration technologiesReview of industry and academic stakeholder opinions involved in the vaccine administration sectorIn-depth discussion of key opportunities and risks for novel vaccine administration technologiesNeedle-free vaccine delivery into and through the skin is an important focus of vaccine research, with key technologies including intradermal patches, microneedles and needle-free liquid, solid and powder injectors. Recognizing the skin as an important immunologic organ, researchers mainly hope for an improved immune response using this approach.
The largest potential for success of mucosal vaccine delivery lies in oral and intranasal administration, while pulmonary vaccination appears less promising due concerns regarding safety and reliable dosing. Careful selection of suitable indications for mucosal delivery routes will be key to success in this challenging sector.
Antigen stability, safety and efficacy are the key hurdles for novel vaccine administration technologies. In times of restricted healthcare budgets, pricing and manufacturing costs of novel vaccine administration systems need to be kept to a minimum. Only the careful selection of suitable indications will offer a route to commercial success.Review profiles of key marketed and development-stage, dermal and mucosal vaccine administration technologies and assess their future potentialGain insight into the current state of vaccine administration technologies and their future opportunities and challengesBenefit from opinions of key industry and academic stakeholders in the vaccine administration field |
|
| Considerable hype as well as skepticism surrounds buzzwords like PHRs, Health 2.0 and social networking in healthcare. While many of the startups in this space will not gain traction, Datamonitor believes some of these online applications will succeed, permanently changing the healthcare landscape.Highlights new, internet based solutions that are impacting healthcareProvides a vision of what healthcare will look like in the futureAnalyzes the business models of healthcare technology startupsHealthcare systems around the world are currently facing a major crisis
With the help of the internet, healthcare assumptions will be flipped on their head
Online solutions increase access, improve quality, decrease costs and empower patientsUnderstand how the internet will impact healthcareIdentify the characteristics of successful startups |
|
| Datamonitor's Healthcare: Global Industry Guide is an essential resource for top-level data and analysis covering the Global Healthcare industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Health Care Equipment, Health Care Supplies and Orthopedics Scope of the Report
* Contains an executive summary and data on value, volume and segmentation for Health Care Equipment, Health Care Supplies and Orthopedics
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Includes five-year forecasts for Health Care Equipment, Health Care Supplies and Orthopedics Highlights * The global health care equipment market generated total revenues of $137.1 billion in 2007. * The global health care supplies market generated total revenues of $93.3 billion in 2007, representing a compound annual growth rate (CAGR) of 4.8% for the period spanning 2003-2007. * The global orthopedics market generated total revenues of $16.2 billion in 2007, representing a compound annual growth rate (CAGR) of 8.7% for the period spanning 2003-2007. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research |
|
| With a considerable patient population and continued government focus on lowering national smoking rates, the nicotine dependence market represents a lucrative opportunity for pharmaceutical companies. With strong uptake since launch in 2006 of Pfizer's Chantix (varenicline), the seven major prescription nicotine dependence market was estimated to total $1.35 billion in 2008.Benchmark key late-stage pipeline nicotine dependence projects against current market leading brands, supported by insight from key opinion leaders.Quantify the future market landscape with sales forecasts of marketed, generics, and key late-stage pipeline drugs to 2018 in the US, 5EU and Japan.Understand key events impacting the future nicotine dependence prescription drug market |
|
| Datamonitor's Pharmaceuticals - North America (NAFTA) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the North American Free Trade Agreement (United States, Canada, and Mexico) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market. Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards
* Compares data from the US, Canada and Mexico, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry Highlights The NAFTA pharmaceuticals market reaches a value of $303.5 billion in 2007. The US is the leading country among the NAFTA bloc, with market revenues of $271.2 billion in 2007 Mexico was the fastest growing country, with a CAGR of 10.2% over the 2004–2007 period.
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research Market Definition The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). |
|
| Datamonitor's Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, China) Pharmaceuticals industry. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market. Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards
* Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry Highlights The BRIC Pharmaceuticals market grew by 14.9% between 2004 and 2007 to reach a value of $41.1 billion. In 2013, the market is forecast to have a value of $50.4 billion, an increase of 14.1% from 2007. China was the fastest growing country with a CAGR of 20.3% over the 2004-2007 period. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research Market Definition The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). |
|
| The healthcare sector in the emirates of Abu Dhabi and Dubai is undergoing drastic changes as a result of the structural and financing reforms that will impact all major actors in the healthcare sector.Overview of the healthcare reforms undertaken in Abu Dhabi and Dubai in order to contain costsStrategic analysis of the changes in interaction between payers, providers of healthcare and pharmaceutical firmsReview of potential pricing and reimbursement strategies to be adopted by insurersCommercial implications of the reforms on all businesses in the UAEReforms undertaken in the UAE will increase healthcare access to all expatriates, and improve the quality of care provided in both the public and private sector. With patients placed at the centre of the reforms, the focus will be on preventive care rather than curative treatment since the UAE is burdened by chronic diseases such as diabetes.
Greater involvement of private insurers through compulsory employer financed health insurance will mature the health insurance industry. Datamonitor believes that insurers will emerge as the dominant influencer of the healthcare industry as relationships between providers, payers and Pharma change as a result of the reforms.
With the implementation of tighter pricing and reimbursement controls, the pharmaceutical market is expected to evolve, driven by initiatives to increase the use of generics and stricter prescribing practices. However, consumer attitudes towards generic drugs will need to be changed for such cost-containment measures to be fully realized.Understand how the development of the UAE insurance industry will impact your businessAnticipate stakeholder interactions that will change as a result of the healthcare reformsIdentify opportunities to increase revenue streams by developing corporate strategies that are in line with Datamonitor's recommendations |
|
| Datamonitor expects commercial strategies in the cardiovascular and metabolic markets to become increasingly important as the markets mature. The report details strategies used by pharmaceutical companies to capture market share, to differentiate brands from the competition, for revenue maximization and for the defense of brand revenues from generic competition.Analysis of company and brand marketing positioningAnalysis of methods employed to bolster R&D pipelinesAnalysis of the methods used to achieve brand differentiation and revenue maximization.To maximize the effectiveness of their sales forces, pharma companies can adopt a number of approaches to position their teams within a therapy area. These approaches can range from covering the whole of a therapy area, targeting a suite of products within one disease, to the highly specialized development of niche products for orphan indications
Pharmaceutical companies can focus their portfolios by either choosing a broad 'shots-on-goal' approach, or opting for a narrower strategy focusing on a single drug class.
Despite in-house drug development remaining the core option for drug companies to stock their development pipelines, the distribution of marketed drugs sourced internally or externally (merger and acquisition, in-licensing and co-development) varies greatly between the leading companies in the cardiovascular and metabolic marketsUnderstand key company positioning strategiesIdentify optimal R&D strategiesIdentify effective methods for restricting the impact of generics following patent expiry |
|
| In recent years, Pharma has begun to adapt its business model in response to growing industry constraints and the decline of the primary-care focused blockbuster therapy. This process of change has recently been disrupted by unprecedented challenges caused by the global economic downturn, and by President Obama's planned overhaul of the US healthcare system.Provides key strategies and trends shaping the future of the pharmaceutical industryExamines the impact of the Obama administration on US healthcare, and the implications for PharmaAssesses the implications of the current economic and financial situation on healthcareAnalyzes key growth drivers and resistors set to shape Pharma's futurePharma has begun to implement strategies to evolve from its traditional model towards a new model: Pharma 2.0; defined as a leaner, globalized entity, whose increased scale is achieved 'virtually' rather than through accretion. Pharma 2.0 is focused on targeting high-growth markets through collaboration, and 'smart' sales and marketing strategies.
President Obama's healthcare reform proposals will have a negative impact on Pharma's future growth. While the likely expansion in public healthcare to capture the estimated 15% of the US population who are uninsured will grow future drug revenues, generics companies and eventually biosimilars manufacturers will be the ultimate winners.
The industry now also faces added economic pressures, with Pharma having to implement a swathe of cost-cutting strategies. Also, due to worsening economic conditions in the US, uninsured patients are now even less able to cover the costs of their healthcare, and are making personal cost-cutting, ultimately impacting pharmaceutical sales.Gain insight into how the unprecedented challenges of the global recession and President Obama's US healthcare overhaul will affect PharmaUnderstand what strategic steps Pharma companies are implementing to maintain and grow their profitabilityIdentify the strategic shifts the Pharma industry is taking in its transition towards Pharma 2.0 |
|
| Low disease awareness, poor diagnosis rates, combined with a lack of pharmaceutical industry involvement, has kept celiac disease from the limelight. However, this is changing as evidenced by Shire's recent involvement in the pipeline. Datamonitor believes a drug for celiac disease is up to 5 years away and this untapped gastrointestinal indication has the potential to become a lucrative market.Review of epidemiology, issues with diagnosisboth current techniques and those with future potentialand management of celiac disease, are discussedCommercial assessment of celiac disease, including market access scenarios and patient number forecastAn overview of unmet needs, the celiac disease pipeline and clinical trial designStakeholder opinions based on qualitative interviews with six key opinion leaders in the field of celiac diseaseA drug launch in celiac disease is up to 5 years away. Datamonitor estimates that under optimal conditions drug sales could reach $8 billion by 2019 in the seven major markets. Two market access strategies are available to companies, which are dictated by the targeted celiac disease subpopulation and drug price point.
The pipeline is small, and not advanced past Phase II, but candidates show various approaches to potentially treating celiac disease. Small, venture-backed biopharmaceutical companies power R&D, but Shire's recent in-licensing of the lead pipeline candidate AT-1001 (Alba Therapeutics) shows the promise of future Big Pharma involvement.
Low disease awareness among primary care physicians is a major factor behind low diagnosis rates5% in the US to 25% in the EUin celiac disease. Continued efforts to increase awareness, especially once a drug comes to market, will drive celiac disease diagnosis rates up to 50%-60% by 2019, which will expand the overall patient population.Assess the major diagnostic issues, how these will change and what impact they will have on Datamonitor's celiac disease patient forecast to 2019Understand the key factors and unmet needs that makes celiac disease an area with significant opportunitiesIdentify the companies and drug candidates in this advancing gastrointestinal area, and realize the approaches that are shaping R&D in celiac disease |
|
| This analysis examines the historical and forecast performance for Otsuka in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Otsuka's performance against key rivals in the prescription pharmaceutical sectorConsider how Abilify sales will define Otsuka's continued growth out to 2013, with indirect and direct generic competition remaining a key threatAssess Otsuka's strategy for geographic expansion over 200713 |
|
| This analysis examines the historical and forecast performance for Dainippon Sumitomo in the Rx pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Dainippon Sumitomo's performance against key rivals in the prescription pharmaceutical sectorAssess the effect of the merger with Sumitomo in 2005 on Dainippon's performance.Evaluate Dainippon Sumitomo's strategic aim of expanding away from the Japanese market, which is becoming less favorable. |
|
| This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the Rx drug sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Mitsubishi Tanabe's performance against key rivals in the prescription pharmaceutical sectorAssess how the merger of Mitsubishi and Tanabe has provided scale, re-focused the company's strategic priorities and resource capabilitiesAssess how Mitsubishi Tanabe's extensive launch portfolio is forecast to offset the sluggish sales growth of its aging marketed portfolio |
|
| This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Merck KGaA's performance against key rivals in the prescription pharmaceutical sectorLearn how the continued strong performance of Erbitux will drive the company's prescription pharma business in the period to 2013Evaluate the company's more focused business strategy and see how its extensive restructuring has affected its operating cost and profit margins |
|
| This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Chugai's performance against key rivals in the prescription pharmaceutical sectorEvaluate the impact of Chugai's alliance with Roche, including forecast strong growth for the Avastin franchise in JapanAssess the forecast performance of Actemra, the first monoclonal antibody product to be developed and successfully launched by a Japanese company |
|
| This analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark King's performance against key rivals in the prescription pharmaceutical sectorAnalyze how the invalidation of King's Altace patent in September 2007 will impact the company's revenue performance over 200713Assess how new product launches Remoxy and Acurox could elevate the company to a leader in the highly-fragmented pain market. |
|
| This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark UCB's performance against key rivals in the ethical pharmaceutical sectorAssess how M&A has shaped UCB into a next generation bio-pharmaceutical playerAssess UCB's market leading position in the epilepsy treatment segment and the use of life cycle management in a bid to retain this status |
|
| This analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative informationBenchmark Bayer Schering Pharma's performance against key rivals in the ethical pharmaceutical sectorAnalyse how Bayer's acquisition of Schering AG in 2006 has notably enhanced the healthcare focus as a proportion of its overall businessAssess how increased healthcare focus, merger-related synergies and other cost restructuring will drive a 12.2% CAGR in operating profit over 2007-13 |
|
| This analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Wyeth's performance against key rivals in the prescription pharmaceutical sectorSee how Wyeth's performance to 2013 will be hampered by the demise of four key products, cancelling out growth from a relatively promising pipelineLearn how the company's operating profit growth will be boosted by a strategy of continued cost containment |
|
| This analysis examines the historical and forecast performance for Merck & Co. in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Merck & Co.'s performance against key rivals in the ethical pharmaceutical sectorAssess the impact of generic erosion across key Merck & Co. brands over 07-13 and how this threat will mitigate sales growth from new launchesAnalyze how Merck & Co will improve its operating performance over 07-13 despite a flat sales growth performance, via significant cost restructuring. |
|
| This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Roche's performance against key rivals in the prescription pharmaceutical sectorSee how the Swiss company will continue to benefit from its relationship with the US biotech GenentechLearn how the company's three key monoclonal antibodies, MabThera/Rituxan, Herceptin and Avastin, will account for over 70% of sales growth to 2013 |
|
| This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark GlaxoSmithKline's performance against key rivals in the ethical pharmaceutical sectorAssess the threat posed by generic competition to GlaxoSmithKline's prescription pharmaceutical businessAnalyze the future strategic direction of GSK, namely an enhanced vaccine offering, geographic diversification and increased biologics presence |
|
| This analysis examines the historical and forecast performance for Sepracor in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Sepracor's performance against key rivals in the prescription pharmaceutical sectorAssess the challenges facing the company's enantiomer-driven portfolioSee how externalization strategies will help Sepracor to secure its long-term profitability |
|
| This analysis examines the historical and forecast performance for Menarini in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Menarini's performance against key rivals in the prescription pharmaceutical sectorDiscover how the company's business model continues to drive sales growth across the established and emerging European marketsAssess Menarini's position in the hypertension market and the various challenges that its broad antihypertensive portfolio could face |
|
| This analysis examines the historical and forecast performance for Solvay in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Solvay's performance against key rivals in the prescription pharmaceutical sectorSee how sales growth driven by increased penetration of the US dyslidemia market will be offset by a growing generic threat and poor R&D productivityLearn how Solvay plans to continue raising its operating profit margin, already improved by an increased pharma focus, by pursuing efficiency savings |
|
| Tuberculosis is a major cause of illness and death worldwide, but despite 14.4 million prevalent cases, 9.2 million new cases and 1.7 million deaths in 2006, the small and rapidly declining burden of disease in the seven major markets has limited drug and vaccine development activities until recently.An overview of the epidemiological trends in the seven major markets and rest of worldDiscussion of the diagnostic methods for latent and active infectionA review of current treatment regimens and antibiotic agents in development for TBAn assessment of vaccines in development for TB and the immunization strategies being investigatedDrug developers and research foundations are trialling several novel vaccines and therapeutic strategies for the prevention and treatment of TB. Immunization approaches used include boosting the old BCG vaccine in order to provide better, lasting protection; new vaccines to prevent adult pulmonary TB; and immunotherapeutic vaccines.
In 2007 the global TB market was worth approximately $300 million, expanding at a modest CAGR of 2.2% from 2004-2007. Given the low incidence of TB in the seven major markets, they only accounted for around 40% of total sales; the majority of revenues (60%) was achieved in the rest of world which includes the majority of the high burden countries.
The most significant commercial opportunity exists in second line therapy, since the drugs currently used in this setting suffer from greater toxicity and less efficacy compared to first-line agents. Drugs that reduce the duration of therapy and are active against drug resistant TB have a strong chance of gaining significant commercial success.Understand the current TB market dynamics and future commercial opportunitiesExamine unmet needs in the TB vaccines and antibiotics market and the extent to which pipeline products are addressing theseIdentify the key vaccines and antibiotics in development for TB and their likely positioning |
|
| The opioids market is set to grow from $9.6 billion in 2008 to $11.9 billion in 2018 across the seven major markets. However, the number and diversity of products in late-stage development will limit the commercial potential of individual brands simply due to saturation and price competition in each opioids market.Analysis of the likely impact that recent events will have on the future opioids marketIncludes forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2018Identification of future market events that are expected to affect opioid revenues. |
|
| Despite an explosion in the number of drugs and treatment strategies available, pulmonary arterial hypertension is still a rapidly fatal condition for a small, hard to identify patient group. A small clinical elite is currently leading the way in advancing treatment outcomes, and is central to determining which new treatment strategies are used.Defining the key clinical characteristics of the pulmonary arterial sector that present a unique commercial challengeTranslation of critical clinical issues into pertinent practical considerations for both incumbent players and new market entrantsInsight into the challenge of determining a patient potential in the context of a miniscule diagnosed population and a phenomenal "at-risk" populationAssessment of future directions in management and the changing roles of therapiesThe estimated 8,11516,186 diagnosed pulmonary arterial hypertension patients across the US, Japan, France, Germany, Italy, Spain and the UK represent a fraction of the 28.0135.6 million group known to be at elevated risk. Identifying the true patient potential within known high risk groups remains highly problematic.
A small, but relatively powerful clinical community has brought structure, order and an increasing influence to bear on management through a few specialist centers. This internationally cohesive group has been responsible for laying the foundations for substantial volumes of data pertaining to patients managed in increasingly standardized ways.
A high number of approved and late stage pipeline products, and the increasing exploration of combination therapeutics places a higher emphasis than normal on the perceptions of specialist clinicians, who will increasingly need to triage their attentions to the most promising avenues for improving outcomes.Understand the challenges in aligning product positioning to the demands of the future clinical paradigmIdentify development strategies that allow optimal buy-in from an increasingly important clinical communityQualify market expectations against the practical realities of targeting this fragmented, niche patient population |
|
| The opioids market is set to grow from $9.6 billion in 2008 to $11.9 billion in 2018 across the seven major markets. However, the number and diversity of products in late-stage development will limit the commercial potential of individual brands simply due to saturation and price competition in each opioids market.This report gives a strategic analysis of the likely impact that recent events will have on the future opioids marketIncludes forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2018Provides a global opioids market snapshot, and analysis of growth trends in key markets outside of the seven major pharmaceutical marketsConclusions are supported by key opinion leader commentPurdue/Mundipharma/Napp Pharmaceutical's OxyContin (oxycodone controlled-release) is forecast to regain the prescriptions lost to generics following re-establishment of market exclusivity in the US. Sales peak at around $3 billion in 2009 across the seven major markets.
King Pharmaceutical's anti-abuse opioid franchise looks set to reach blockbuster levels over the forecast period. With combined sales of Remoxy (oxycodone controlled-release), Embeda (morphine extended-release and naltrexone) and the immediate-release opioid Acurox (oxycodone and niacin) forecast to generate around $1 billion per annum by 2018.
Reinvigoration of the short- and rapid-acting opioids market following approval of Fentora for non-cancer pain in the US, and the entry of regional specialist companies in the 5EU, will expand the market beyond that achieved by Cephalon to date.Quantify the current size of the global opioids marketAssess the impact of recent and anticipated events (patent expiries, new product launches, regulatory approval) on opioid brand salesUnderstand the country-specific impact of key events in the opioids market during the forecast period 2009 to 2018 |
|
| This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Genzyme's performance against key rivals in the prescription pharmaceutical sectorSee how the company's core products of Cerezyme, Fabrazyme and Myozyme will continue to act as the primary sales growth driversEvaluate Genzyme's 'spread risk' strategy of diversifying into new therapy areas through a combination of licensing deals and M&A |
|
| This analysis examines the historical and forecast performance for Genentech in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Genentech's performance against key rivals in the prescription pharmaceutical sectorAssess the importance of Avastin Genentech's commercial performance over 2007-13Analyze how Genentech will continue to utilize horizontal indication broadening across its core portfolio to drive sales growth |
|
| This analysis examines the historical and forecast performance for Amgen in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Amgen's performance against key rivals in the ethical pharmaceutical sectorAssess how Amgen's commercial performance out to 2013 will be impacted by recent safety concerns relating to the ESA product classAnalyze Amgen's diversification strategy which will be heavily reliant on the launch of denosumab indicated for osteoporosis and bone metastases |
|
| This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Celgene's performance against key rivals in the prescription pharmaceutical sectorUnderstand how Revlimid will drive the company's performance out to 2013See how the acquisition of Pharmion will affect Celgene's strategy |
|
| This analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Shire's performance against key rivals in the ethical pharmaceutical sectorAssess the impact of generic competition to Shire's blockbuster ADHD drug, Adderall XR, over 200713Analyze the impact of recent acquisitions (TKT, New River Pharmaceuticals, Jerini) on Shire's financial and sales performance over 200113 |
|
| This analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Alcon's performance against key rivals in the prescription pharmaceutical sectorSee how new launches have driven Alcon's impressive growth throughout the historic periodAssess the benefits of Alcon's tight therapeutic performance and see how this will affect its performance out to 2013 |
|
| This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Servier's performance against key rivals in the prescription pharmaceutical sectorLearn how, Coversyl, the company's biggest growth driver over 2001 to 2007 will become its biggest growth resistor during the forecast periodSee how Servier's strong position in the French generics industry will become increasingly strategically important |
|
| This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Boehringer Ingelheim's performance against key rivals in the prescription pharmaceutical sectorEvaluate the impact of generic competition for the key product Flomax, particularly in light of recent patent expiry for another key product, MobicAssess how Boehringer could utilize externalization strategies to bolster its long term sales growth and support its internal product development |
|
| This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Schering-Plough's performance against key rivals in the ethical pharmaceutical sectorAnalyze the impact of Schering-Plough's acquisition of Organon Biosciences, completed in 2007Assess the diversity of Schering-Plough's product portfolio in light of forecast declining sales for its recent sales growth driver Zetia/Vytorin |
|
| This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Abbott's performance against key rivals in the prescription pharmaceutical sectorAssess how M&A activity will drive Abbott's long term growth performance in the prescription pharmaceutical marketEvaluate the commercial importance of Humira in light of exposure to generic competition across Abbott's product portfolio |
|
| This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Johnson & Johnson's performance against key rivals in the ethical pharmaceutical sectorAnalyze how J&J will implement life cycle management strategies across its portfolio as a means to combat patent expiries and generic competitionAssess J&J's diverse healthcare offering and how this will act to maintain operating growth despite flat forecast revenue expansion for Rx pharma |
|
| This analysis examines the historical and forecast performance for Pfizer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Pfizer's performance against key rivals in the ethical pharmaceutical sectorAssess how Pfizer's M&A driven growth strategy will continue to impact the company's commercial performance out to 2013Analyze the impact of patent expiry for Pfizer's flagship product Lipitor, which accounted for c.29% of the company's prescription drug sales in 2007 |
|
| Not only is Pharma facing a continued slow down in sales growth in the seven major markets, but erosion of branded drugs by generics follow patent expiry is increasing, driven by evolving payer initiatives to incentivize generic use.Understand brand erosion according to formulation, therapy area and brand value in the seven major marketsAnalysis of the top 10 most eroded brands during Q2 2006 and Q2 2008Overview of prices of generic drugs in the seven major marketsCase studies of successful and unsuccessful strategies to protect the branded franchiseTough competition, a focus on cost-containment and incentives for prescribing generic drugs, make the US, UK and Germany prone to severe brand erosion immediately after patent expiry. The US saw the strongest erosion for both oral and injectable drugs, reflecting the high level of generic substitution in the US compared to other markets.
Across all markets, the higher the annual sales of a branded drug, the more intense its generic erosion at patent expiry. Competition among generic players targeting high value drugs is also fierce, leading to a rapid decline in generic prices as more players enter the market.
Overall, the most heavily eroded drugs by therapy area in the US were respiratory drugs, due to the large market size and low entry barriers for generics companies, while CNS drugs experienced the lowest levels of erosion.Identify the different factors that drive brand erosion in the seven major markets in the first 2 years of generic entryUnderstand the average level of erosion a brand can expect to face following generic incursion, depending on its formulation, value and ATC groupEvaluate the success of various reformulation strategies in protecting brand franchise from generic competition |
|
| Only 15-20% of pancreatic cancer patients have resectable disease, therefore most receive systemic therapy. Gemzar (gemcitabine; Eli Lilly) forms the current standard of care for advanced disease. Despite this, no treatment is truly effective, with five-year survival at 5% for all stages of disease. Significant unmet needs therefore remain, with ample commercial opportunities for drug developers.Pancreatic cancer overview, including definition, risk factors, epidemiology forecasts and discussion of unmet needsCurrent diagnosis and treatment of pancreatic cancer, including drug regimens used by stage and ongoing controversiesExamination of the late-phase pancreatic cancer pipeline and market opportunities for drug developersStakeholder opinions based on qualitative interviews with key opinion leaders in the field of pancreatic cancerGemzar is the current standard of care for unresectable locally advanced and metastatic pancreatic cancer. Despite this, Gemzar is only associated with median overall survival of 5.7 months and a one-year survival rate of 18%. It is therefore clear that treatment of pancreatic cancer continues to be plagued by high levels of unmet need.
Other lines of therapy in pancreatic cancer remain ill defined due to a lack of definitive randomized clinical trial data. Controversy persists regarding the use of neoadjuvant versus adjuvant therapy, while the role of radiotherapy alongside chemotherapy in these settings continues to provoke debate.
The pancreatic cancer pipeline is relatively active, with six Phase III agents. Despite this, Gemzar is set to retain its leading status for the foreseeable future. While promising Phase II results have been shown, this has yet to be translated into Phase III efficacy. As a result, no pipeline agent has yet shown the potential to replace Gemzar.Identify the limitations of current therapy available to pancreatic cancer patients and the potential of future therapyUnderstand current epidemiological trends in pancreatic cancer and ongoing treatment controversiesAssess the opportunities for innovative targeted therapies in the pancreatic cancer market, particularly in metastatic disease |
|
| Patient perception of disease severity drives treatment-seeking behavior in psoriasis. New therapeutic options targeting specific mechanisms are set to reshape severe psoriasis therapy. However, current biologics have not undermined first-line topical therapy. In addition to efficacy, reimbursement plays a crucial role in physicians' prescribing decisions.Opinion from 180 practicing dermatologists, each treating at least 40 psoriasis patients per monthIncluding data from physicians and opinion leaders across the seven major markets of the US, Japan, France, Germany, Spain, Italy and the UKAnalysis of psoriasis population attributes, physicians' prescribing decisions, therapy outcomes and treatment satisfactionBrand analysis of key pharmaceuticals used in psoriasis, including biologics and branded topical formulationsThe low estimated diagnosis rate of 54% reflects a lack of treatment-seeking by mild sufferers. Despite nearly 10 million diagnosed patients, the market value of psoriasis is constrained by reliance on generic and non-prescription treatments in mild disease.
Biologics' risk-benefit and cost-benefit ratios are coming under review. Humira (adalimumab) and Stelara (ustekinumab) stand to benefit from the withdrawal of Raptiva (efalizumab) from the EU and more stringent labeling in the US. The position of biologics in moderate to severe psoriasis is up for challenge by payers attempting to control costs.
Topical treatments are the foundation of therapy, used alone by at least 82% of mild patients. Phototherapy is a cost-effective treatment option in psoriasis unresponsive to topical therapy. Most physicians surveyed recommend phototherapy to up to 30% of patients, and payers may influence greater use of phototherapy.Understand how patient behavior controls the size of the psoriasis marketInterpret physicians' priorities in prescribing personalized psoriasis treatment regimensAssess the regional dynamics of therapy choice in psoriasis, dictated by product availability, regulation and reimbursement |
|
| Factors influencing a prescribing decision can diverge from clinical facts. In the highly competitive autoimmune area, misconceptions and physician habits can result in loss of sales. Targeted detailing of specialist physicians, differentiating by indications is the key to success. Datamonitor has surveyed gastroenterologists, rheumatologists and dermatologists on attribute and brand perceptionsOpinion from 540 physicians including rheumatologists, dermatologists and gastroenterologistsData from physicians and opinion leaders across the seven major markets of the US, Japan, France, Germany, Spain, Italy and the UKAnalysis of the extent to which certain factors affect physician prescribing, with comparison across each specialtyAnalysis of the opinion dynamics for the key brands used across prominent autoimmune diseasesEfficacy and safety factors will always be any physician's main consideration, drawing an average of 62% of the weighting by importance when prescribing a biologic therapy. Actemra's positive perception from rheumatologists, despite known side-effects, exemplifies the importance of informing physicians about issues, rather than masking them.
New TNF inhibitors in autoimmune disease battle against 'me-too' status and the strong positive opinion of the existing three products in the category. Humira leads the group with a total score 16% above the average. Newcomer anti-TNF options Simponi (golimumab) and Cimzia (certolizumab) are not well perceived by EU prescribing rheumatologists.
Dermatologists' exhibit cynicism towards biologic therapies, scoring all brands lower than other physician types, less surprising when considering the nature of most psoriasis therapies. However, Centocor's Stelara (ustekinumab) is highly anticipated with dermatologists scoring it 40% above average in terms of predicted efficacy.Target physicians more efficiently by understanding the differences in brand perception between physician specialtiesTailor your marketing message to the attributes most important to prescribing physiciansAssess the regional dynamics of physician perception in autoimmune disease across the seven major markets |
|
| With cystic fibrosis patients still dying prematurely and only two products currently approved for the treatment of this disease, the market is wide open for new entrants. Not only will novel symptomatic treatments and re-formulations lead to improved treatment paradigms, truly disease-modifying compounds are in late-stage development and will significantly change the market.Disease background, segmentation and epidemiology of cystic fibrosis in the US and five major European countriesSummary of the drug classes currently used for the treatment of cystic fibrosis lung disease and cystic fibrosis-related pancreatic insufficiencyAn overview of unmet needs, the cystic fibrosis pipeline and clinical trial designIn-depth outline of around 85 compounds studied for the treatment of cystic fibrosis by the pharmaceutical industry and academic institutesIt is clear that, although cystic fibrosis only affects around 52,000 patients in the five major European countries and the US, the pipeline is highly active with over 50 pharmaceutical companies involved. As many as 13 of the compounds studied by the pharmaceutical industry are currently in late-stage development.
The promise of gene therapy has yet to materialize, and mutation specific correcting therapy is eagerly anticipated. There are at least four protein repair treatments in clinical development for three different classes of mutations, although it is likely that combination strategies are required in order to enhance their efficacy.
Disease-modifying treatments that are not mutation-specific include alternative chloride channel activators and epithelial sodium channel inhibitors. Compounds in the former class are furthest along in development; however, it is likely that a combination of the two classes will be necessary for full correction of the airway surface liquid.Understand and capitalize on clinical unmet needs in the market through both lifecycle management of marketed drugs and new product developmentAssess the cystic fibrosis pipeline both through background reading and via the interactive Excel-based pipeline summaryIdentify physician awareness and perceptions surrounding future treatments and new developments for cystic fibrosis |
|
| This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Bristol-Myers Squibb's performance against key rivals in the ethical pharmaceutical sectorAssess the level of generic exposure faced by Bristol-Myers Squibb out to 2013, driven primarily by patent expiry for its lead product Plavix in 2011Analyze BMS's biologics-led growth strategy out to 2013, driven by its existing access to Erbitux and Orencia and new biologic launches also |
|
| This analysis examines the historical and forecast performance for Eli Lilly in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Eli Lilly's performance against key rivals in the prescription pharmaceutical sectorAssess the commercial outlook for key new launch products Effiant and Byetta LAREvaluate Eli Lilly's ability to overcome the adverse impact of patent expiry for Zyprexa and other key franchises over the period 2011-13 |
|
| This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark AstraZeneca's performance against key rivals in the ethical pharmaceutical sectorAssess the commercial impact of AstraZeneca's recent movement into the biologics market, spearheaded by its acquisition of MedImmuneAnalyse the exposure of AstraZeneca's blockbuster portfolio to patent expiration and generic competition through to 2013 |
|
| This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Daiichi Sankyo's performance against key rivals in the prescription pharmaceutical sectorAssess the importance of Daiichi Sankyo's olmesartan antihypertensives franchise (Benicar, Benicar HCT and Azor) is to the company's outlookEvaluate the prospects of the company's key launch product, Effient (prasugrel) which is being co-developed with Eli Lilly |
|
| This analysis examines the historical and forecast performance for Astellas in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Astellas's performance against key rivals in the prescription pharmaceutical sectorDetermine the long-term outlook of Astellas's diverse prescription pharmaceutical portfolioEvaluate the unique corporate strategies being pursued by Astellas in its domestic Japanese market and in the US |
|
| This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Eisai's performance against key rivals in the prescription pharmaceutical sectorSee how the loss of patent protection on Eisai's blockbuster products Aricept and AcipHex/Pariet will impact Rx revenue performance over 200713Evaluate Eisai's long-term growth potential following the acquisition of US companies Morphotek and MGI Pharma in 2007 and 2008 respectively |
|
| This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.Benchmark Takeda's performance against key rivals in the prescription pharmaceutical sectorDetermine the impact of blockbuster patent expiries on the long-term financial performance of Japan's number one pharmaceutical companyScope out the various strategies being implemented by cash-rich Takeda as it looks become a leading player in the fast-growth oncology space |
|
| Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0.9% in the seven major markets.A detailed clinical and commercial assessment of all key cardiovascular and metabolic therapy areas.An analysis of the portfolios of top 10 leading cardiovascular and metabolic companies.Sales based sales forecasts for all key cardiovascular and metabolic active agents in the seven major markets to 2017.The cardiovascular and metabolic market is rapidly maturing with the total market revenues forecast to grow only by 0.9% CAGR between 2007 and 2017. This is despite growth in the use of cardiovascular and metabolic drugs forecast to grow by 3% CAGR over the same time period.
Market growth will be driven by strong antithrombotics and antidiabetic pipelines where significant clinical unmet needs remain. The antidiabetic is forecast to generate close to $11 billion in 2017 with the antithrombotic pipeline generating $10 billion in 2017.
Antidiabetic therapies are forecast to be become the highest revenue generators in 2017 as the primary care markets of hypertension and dyslipidemia become almost completely genericized. 50% of the top 10 brands in 2017 are forecast to be antidiabetics.Qualify and quantify the Top 10 cardiovascular therapy brands across the seven major pharmaceutical markets from 2007 to 2017.Understand key drivers and predict the future performance of leading products.Assess the remaining market opportunities, where established therapies and other developmental compounds fail to address key unmet clinical needs. |
|
| Cancer cachexia is a muscle and fat wasting syndrome that affects the majority of incurable cancer patients and adversely impacts treatment outcomes, survival and quality of life. Current treatment options for cancer cachexia are limited. The lack of a universal objective definition and the low profile of the condition among oncologists have restricted advances in treatment.Cancer cachexia overview, including definition of the condition, pathophysiology and patient population estimates in the seven major marketsTreatment of cancer cachexia, including discussion of drug therapies currently available and unmet needsExamination of cancer cachexia pipeline activity including profiles of late-phase pipeline drugs and clinical trial design discussionStakeholder opinions based on qualitative interviews with opinion leaders in the field of cancer cachexiaThe lack of effective drug therapy is the biggest unmet need in cancer cachexia. Megestrol acetate is used off-label but does not increase lean body mass. Corticosteroids are also used off-label, but their side effect profile restricts use to a short-term basis. A multimodal approach to therapy may be the best way of improving treatment outcomes.
Several different types of clinician are involved in the management of cancer cachexia, but oncologists have the greatest influence. Drug companies should raise awareness of cachexia among oncologists to improve treatment and build a market. This may also help to promote a more universal multidisciplinary team approach to cancer cachexia care.
Developers of cancer cachexia drugs face several large hurdles. The lack of a universal, objective definition of cancer cachexia means that there is uncertainty over which patients to recruit for clinical trials. Furthermore, controversy surrounds clinical trial endpointsit is unclear which endpoints should be use and how to measure a response.Assess the size of the cancer cachexia population (both overall and for specific tumor types) in the seven major marketsUnderstand unmet needs in cancer cachexia and the challenges facing developers of drugs for cancer cachexiaIdentify products in clinical development for cancer cachexia. Consider, assess and react to opportunities and risks influencing their potential |
|
| With the Asia-Pacific markets growing rapidly, they are becoming increasingly attractive for Pharma to enter. However, a number of key P&R developments and reforms are set to change the healthcare environment in the next few years, as healthcare is made more accessible to the poor and elderly.Insight into pricing and reimbursement strategies in Australia, Singapore, China and Hong KongAnalysis of drivers and barriers for entering Australia, Singapore, China and Hong KongOverview of healthcare systems in Australia, Singapore, China and Hong KongIdentification of trends shaping national P&R strategies and their impact on branded PharmaIn Australia, a high level of evidence is needed to show clinical and cost effectiveness, thus clearly pointing to a barrier for entering the Australian market. It is essential that a new medicine is cost effective against the standard of care, therefore solid head-to-head clinical trial data must be presented to have a successful listing.
Recent changes by the Chinese National Development and Reform Commission (NDRC) means that the financial rewards for the multinationals will be jeopardized. The pricing authority has planned another round of price reductions, but for the first time, this will also affect imported drugs.
Singapore's affluent population translates into high per capita spending on healthcare and a preference for branded drugs. Its healthcare financing system based on co-payments discourages excessive consumption and acts as a measure of cost-containment.Understand the recent changes in the P&R environment in the key Asia-Pacific marketsAnalyze recent trends in healthcare in Asia-Pacific and the impact on branded pharmaIn-depth and up to date information on P&R regulations through interviewing local industry executives |
|
| The antithrombotic market is expected to grow to $22 billion by 2017. The growth will mainly be due to the introduction of new agents onto the market, such as prasugrel and rivaroxaban, which will offer significant improvements over the current standards of care (Plavix (clopidogrel) and warfarin, respectively).Quantify the future size and understand the background of the antithrombotics marketUnderstand the commercial landscape in terms of new product potentialUnderstand the barriers to uptake for novel antithrombotics. |
|
| Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0.9% in the seven major markets.A detailed clinical and commercial assessment of all key cardiovascular and metabolic therapy areas.An analysis of the portfolios of top 10 leading cardiovascular and metabolic companies.Sales based sales forecasts for all key cardiovascular and metabolic active agents in the seven major markets to 2017. |
|
| Datamonitor research points to this sector, beleaguered by patent expiries, barriers to market entry and uptake, becoming increasingly inclement towards branded drugs. Generic incursion has taken a heavy toll on the market at a number of levels. The volume of key brands facing generic competition makes it even harder for remaining products to court large revenues in the community sector.Analysis of the retail market for antibacterials across Japan, US, France, Italy, Germany Spain and the UKProduct by product analysis of the key marketed brands with a 10 year forecastAssessment of key developments shaping the sector, e.g., generic substitutionDiscussion of opportunities and threats on a general, regional and national levelThe community market for antibiotics is declining at a CAGR of -3% over the 2003 07 period. This is the mark of a sector already saturated by generic product. Over the 2003 07 period generic share of the market has grown from 30% of the market, to 40% of seven major market revenues, and from 56% to 65% of volume share.
Aside from the substantial difference in market sizes between the US, Japan and the five major EU markets, the nature of community antibacterial sales across the three territories varies greatly. For example, market shares fluctuate substantially depending on whether volume or value statistics are considered.
In 2007, the US accounted for a much higher proportion of value share of the market (57%) than volume share (47%), while relatively speaking, the 5EU accounted for a much lower proportion of value share (27%) by comparison to volume share (37%)pointing to substantial differences in the average cost per standard unit.Learn about the extent of the still expanding generic domination of the sector and how to counter itAssess the regional and national differences in terms of class and brand preferences and where the opportunities lieReview the changes in class sales that signal the shift in prescribing practices |
|
| The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017.Understand current and future Hepatitis C market dynamicsGain insight into the unmet needs of HCV patients and the extent to which pipeline drugs are addressing these issuesAssess current and future market size and the impact of new drug launches |
|
| Datamonitor's Orthopedics: Global Industry Guide is an essential resource for top-level data and analysis covering the orthopedics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis. Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards
* Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).
* Includes a five-year forecast of the industry Highlights The global orthopedics market grew by 8.1% in 2007 to reach a value of $16.2 billion. In 2012, the global orthopedics market is forecast to have a value of $22.9 billion, an increase of 41.7% since 2007. Spine implant sales account for 31.1% of the global orthopedics market's value. Americas accounts for 71.3% of the global orthopedics market's value. Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research Market Definition The orthopedics market covers the hip, knee, shoulder, spine, and trauma implant sectors. The market is valued at manufacturers' selling price (MSP).The hip implants sector consists of primary (including cemented, hybrid and cementless) revision and endoprosthesis implants.The knee implants sector consists of primary (including cemented, hybrid and cementless) revision and unicondylar implants. The shoulder implants sector includes total and partial replacement implants.The spinal implants sector consists of fusion cages, rods, hooks, plates and screws.The trauma implants sector includes IM nails, plates and screws. For the purpose of this report the Americas comprises Brazil, Canada, Mexico and the US. Europe comprises Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden and the UK. Asia-Pacific comprises Australia, China, Japan, India, Singapore, South Korea and Taiwan. The global figure comprises the Americas, Asia-Pacific and Europe. |
|
| Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis. Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards
* Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).
* Includes a five-year forecast of the industry Highlights The global generics market grew by 12.3% in 2007 to reach a value of $108 billion. In 2012, the market is forecast to have a value of $178 billion, an increase of 64.7% since 2007. The ethical generic segment dominates the market with 76.1% share. The Americas generate 40.1% of the global genericas market's value Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research Market Definition The value of the generics market consists of all sales of generics drugs at ex-manufacturers prices. The market does not include animal healthcare products. Datamonitor defines a generic as a product, which is an officially approved copy of an original product whose patent has expired, marketed either as a brand or using the generic name. This definition excludes multi-source copy products that make up much of markets such as India, Spain and Italy. All currency conversions have been calculated at constant 2007 average exchange rates. For the purpose of this report the Americas comprises Brazil, Canada, Mexico and the US. Europe comprises Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden and the UK. Asia-Pacific comprises Australia, China, Japan, India, Singapore, South Korea and Taiwan. The global figure comprises the Americas, Asia-Pacific and Europe. |
|
| PharmaVitae universe Rx sales are forecast to expand at a 2007-13 CAGR of 2.4%, down 7.6 percentage points from 2001-07. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.Analysis of the sales outlook for the PharmaVitae universe of leading prescription pharma companies to 2013Assessment of the impact of future launches and patent expiries on sales growth compared to historical trendsSegmentation of the market by therapy area and molecule type to assess high- and low-growth sectors of the industryAssessment of the impact of cost-cutting on operating profit growth in an environment of low and sometimes negative sales growthThe increasing assault of generics on leading pharma players' staple diet of small molecule products will prompt a shake-up of the industry. Companies' success will be heavily linked to their exposure to this generic threat, with biologics and niche players enjoying the greatest insulation and therefore often the highest growth.
Many companies not in these hot sectors of the industry will be compelled to pursue cost-cutting to maintain previous levels of operating profit growth and some may resort to M&A activity to bolster sales performance and/or strategically realign themselves.
However, recourse to M&A should not be surprising when looked at in the historical context, as this has already acted as the PharmaVitae universe's primary growth driver in the period between 2001 and 2007, accounting for a greater proportion of growth than internal R&D operations.Gain a true understanding of the threats facing the pharmaceutical industry's sales performance and which sectors will be most heavily impactedAssess the effectiveness of cost-cutting programs on operating profit performance in a period of low sales growthEvaluate the impact of M&A on companies' historical performance and see how low top-line sales growth could prompt a further wave of consolidation |
|
| This Datamonitor study examines top business challenges, IT budget outlooks and spending priorities among healthcare providers in North America and Europe. It is based on the results of Datamonitor's Business Trends primary research, conducted in Q4 of 2008.An annual survey of 150 hospital IT directorsGeographic coverage includes the US, Canada, France, Germany, Spain and the UKWhile only a handful of hospitals are significantly increasing their IT budgets, the majority are not cutting back on IT investments
While EHRs continue to be a priority for survey respondents, hospitals are also recognizing the need for HIE solutions and CDSEffectively map IT solutions to address healthcare business pain pointsGain firsthand insight on spending priorities and budget outlooks of hospitalsTarget healthcare customers more effectively |
|
| RTLS, particularly the use of radio frequency identification (RFID), have been a hot topic in healthcare circles recently. Despite the buzz, however, adoption has been slow. This report will examine RTLS in healthcare and determine if the hype around it is deserved.Identifies the key barriers to greater RTLS adoptionProvides examples of RTLS applications in healthcareAnalyzes the current trends in the RTLS marketDecreased costs, increased efficiencies and better patient care are driving RTLS adoption
RTLS is a 'nice to have,' not a 'must have' yet
Increased standardization and advanced functionality are trends in the RTLS marketUnderstand where RTLS is today and where it will be in the near futureIdentify strategies that will increase RTLS adoption |
|
| Pharmaceutical companies are now divesting non-core assets such as medical devices and manufacturing plants in an effort to cut costs and focus on core strategies, primarily drug development. However, while some Pharma companies are narrowing their focus, targeting specific disease areas for future growth, others are taking a broader approach in an effort to spread risk and return on investment.Provides an introduction to divestment strategies in the current financial climate, including the drivers and resistors of divesting a company assetOffers recommendations on how the best divest to and how to optimize the divestment processExamines divesture deal trends and values during Q1 2006 to Q3 2008Provides case study analysis of the divesture deal trends during Q1 2006 to Q3 2008Most divesture decisions are made on a reactive basis when a company has no other choice, rather than proactively divesting a growing asset for a high price. Divesting non-core assets is essential to the survival of a biopharma in the current financial setting as it frees up much needed cash to buy assets that support core business needs.
Preparing a company for a divesture involves establishing a dedicated team to deal with the divesture both internally and externally, and requires specific expertise, in order to ease the transition of asset without reducing its value.
Medical devices are the leading type of asset divested in today's US healthcare market. It is increasingly sought after by healthcare companies due to its high value, with medical device sector estimated to be worth over $300 billion, and due to the lower risk involved compared to drug development.Understand why in the current financial climate pharma companies are divesting assets, and the drivers and resistors of divesting and acquiring.Insight in to how best to divest an asset, prepare a company for de-integration and set up transfer agreements to ensure a smooth asset transition.Provides in-depth analysis of the latest divesture deal trends, backed up by case study analysis and Datamonitor opinion. |
|
| The face of ACS continues to change. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS. This report extends the previous year report and unveils the true picture through in-depth analysis of data on over 29,000 ACS patient records in the 5 major European pharmaceutical markets (France, Germany, Italy, Spain and the UK).What are the current definitions, diagnostic methods and treatment approaches of the disease?To what extent are reperfusion therapies, such as PCI (percutaneous coronary intervention) and/or thrombolysis, used?What is the current role of pre-hospital thrombolysis and how is this likely to change in the future?What are the current hospital admission and logistics issues?Cost is no longer the restraining factor or dominant driver of a specific pharmacological strategy. Datamonitor's findings show that the routine use of troponins as cardiac markers has aided this development, with almost 90% of all ACS patients receiving tests for either troponin I or troponin T across the 5EU.
A new definition for myocardial infarction has shifted a significant number of patients from an unclear diagnosis of unstable angina to myocardial infarction moving from an essentially conservative and observational approach to an increase in more aggressive treatment strategies.
Advances in novel imaging techniques provide opportunities to diagnose and treat the most complex ACS cases, however, inter-hospital logistics, necessary specialist training and cost constraints continue to prevent hospitals and clinicians from regular use of those diagnostic methods.Understand current definitions, diagnostic methods and treatment approaches in ACSQuantify current dynamics of hospital logistics, conservative therapies and reperfusion therapies, such as PCI and thrombolysisUnveil the in-depth influencing factors leading to selection of specific pharmacological and interventional strategies |
|
| Sarcomas are a diverse group of rare connective tissue tumors that are categorized as soft tissue sarcomas or bone sarcomas. Although sarcomas represent only 1% of all adult and 15% of all childhood cancers, the development of metastatic disease is a major clinical problem as cure is less likely, particularly for soft tissue sarcomas.Overview of sarcoma subtypes, epidemiology, potential risk factors, disease staging and diagnosisCurrent treatment options for bone and soft tissue sarcomas including GIST with the identification of specific unmet needsGIST has seen the biggest advancement in treatment compared to other sarcoma subtypes. The identification of specific mutations that are key drivers of GIST has permitted the use of two effective small molecule tyrosine kinase inhibitors: Gleevec/Glivec (imatinib; Novartis) and Sutent (sunitinib; Pfizer).Gain an insight into the epidemiology trends of sarcomas as the true incidence is currently unknownIdentify the limitations of current soft tissue and bone sarcoma treatment and consider the remaining unmet needs |
|
| The antithrombotic market is expected to grow to $22 billion by 2017. The growth will mainly be due to the introduction of new agents onto the market, such as prasugrel and rivaroxaban, which will offer significant improvements over the current standards of care (Plavix (clopidogrel) and warfarin, respectively).Description of the competitive landscape in antithrombotics across seven major markets with market definition and overview.Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.Analysis of major events and brand dynamics affecting the antithrombotics market.The antithrombotic market is demonstrating steady growth with CAGR of 8% over the 2004-07 period. The growth can be mainly attributed to the increased uptake of Plavix (clopidogrel) and Lovenox (enoxaparin) in all of the seven major markets.
The US antithrombotic market's share among the seven major markets is forecast to decrease, from 55% in 2007 to 49% in 2017, due to the 5EU volume sales being largest and the patent expiries in the EU not affecting the brand sales to the same extent as in the US.
New agents (especially rivaroxaban and prasugrel) will be successful at gaining a large share of the antithrombotic market, as they offer significant improvements over the current standards of care. In fact, two of the top three revenue-generating antithrombotics are forecast to be agents currently in development.Quantify the future size and understand the background of the antithrombotics marketUnderstand the commercial landscape in terms of new product potentialUnderstand the barriers to uptake for novel antidyslipidemics. |
|
| Driven primarily by continued uptake of UCB's market leading anticonvulsant, Keppra (levetiracetam), seven major market epilepsy revenues grew strongly at a compound annual growth rate of 11.7% to reach almost $3.8 billion in 2007.This report gives a strategic analysis of the likely impact that recent events will have on the future epilepsy marketIncludes epilepsy-specific sales forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2017Provides a global market snapshot by including epilepsy-specific sales analysis for leading brands outside the seven major marketsKey conclusions are supported by key opinion leader commentDespite the failure of UCB's brivaracetam to meet its primary endpoint in a Phase III trial in Unverricht Lundborg disease, the drug is expected to receive strong uptake in patients with refractory partial-onset seizures. Interviewed key opinion leaders remain optimistic about brivaracetam's future prospects.
As a result of Valeant's August 2008 collaboration with GlaxoSmithKline and the release of positive Phase III clinical trial data in September 2008, Datamonitor has upgraded its epilepsy-specific sales forecast for retigabine. However, the drug's likely three-times daily dosing is not expected to be well received by patients and physicians.
D-Pharm's DP-VPA (a prodrug of valproic acid), has not made any known progress through clinical development since 2006. As a result, launch of DP-VPA is expected to take place 1 year later than what was estimated in Datamonitor's previous epilepsy market report and epilepsy-specific sales forecasts for the drug have been downgraded.Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2008 to 2017Quantify the current size of the seven major markets and the trends in the rest of the worldAssess the impact of events, such as patent expiries and new product launches, on the epilepsy-specific sales of key brand name products |
|
| Since the financial meltdown, the relationship between Pharma and Biotech has been turned on its head. Previously, pharma companies had no choice but to license Biotech drugs at high prices in order to fill their sparse late stage pipelines.Overview licensing trends up until the credit crisisStrategic analysis of biotech's funding crisisInsight into how the biopharma market is expected to change and adaptRecommendations and potential financial solutions for biotechWhile Pharma is likely to prefer acquiring biotech targets out right, rather than navigating the road of complex licensing agreements, Datamonitor expects that licensing agreements will remain among Pharma and self sufficient biotech companies. Although snapping up struggling Biotechs through M&A will be a priority for Pharma.
Biotech companies are tackling their funding crises on two fronts; firstly, by cutting costs and reducing their high cash-burn rates, and secondly attempting to access quick cash from external sources. However, this is becoming a tough task.
The lack of deals on the horizon, Biotech's funding crisis, and subsequent loss of confidence in the industry, have all led the market cap of non-profitable US biotech companies to fall by a third since September 2008.Understand how licensing trends have evolved in recent years, and what impact the financial crisis has hadAssess how Pharma and Biotech's relationship has changed and the repercussions of thisIdentify cost saving and cash raising strategies in order to weather the funding crisis |
|
| This report focuses on the challenges of diverse and uncoordinated treatment paradigms for diabetes and the movement to rationalize efforts and establish best practice. Datamonitor uncovers the unique dynamics of the two largest diabetes markets in the GCC; including the impact of regulatory processes such as the healthcare reforms currently being undertaken.Description and analysis of the uniqueness of the antidiabetic markets in the UAE and Saudi ArabiaFragmented healthcare delivery in the UAE and Saudi Arabia presents opportunity for ramping up sales of generics and novel antidiabetic therapeutics.Commercial implications of Datamonitor's extensive findings and our recommendations to maximize sales in these two markets.Diabetes has reached near-epidemic proportions in the UAE and Saudi Arabia, with nearly one out of every five individuals suffering from diabetes in the UAE. In Saudi Arabia, the prevalence is expected to rise to between 40-50% by 2020.
The delivery of treatment for diabetes is highly fragmented, and leads to sub-optimal treatment for patients in the two countries. The fragmentation is caused by a wide variety of issues due to systemic deficiencies, regulatory changes and socio-economic factors.
Datamonitor has explained the commercial implications of its findings and developed recommendations for healthcare firms and regulators to address the many unmet needs in the treatment of diabetes and to ramp up sales and share of market in both UAE and Saudi Arabia.Gain an in-depth understanding of the two largest diabetes markets in the GCC; a strategic growth area for healthcare firms.Increase share of the market by effectively targeting the different segments of the population and demands; branded or generic antidiabetic agents.Maximize current and future revenue streams by targeting the numerous growth opportunities identified by Datamonitor. |
|
| The depression market was valued at around $11.04 billion in 2007 across the seven major markets. Following marginal growth to 2011 ($12.01 billion), the market is forecast to decline in value through to 2017 ($9.81 billion) when brand erosion due to generic incursion affecting all major drug classes used to treat depression finally outweighs the success of reformulations and follow-on products.This report gives a strategic analysis of the likely impact that recent events will have on the future depression marketIncludes depression-specific sales forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2017Provides a global depression-market snapshot, and analysis of growth trends in key markets outside of the seven major pharmaceutical marketsConclusions are supported by key opinion leader commentDatamonitor has upgraded its depression-specific Abilify and Seroquel forecasts following positive clinical trial data in depression for both atypical antipsychotics, and the observation that regulatory approval of Abilify as an adjunct to antidepressants in depression resulted in an increase in the brand's quarterly sales growth rate.
Servier and Novartis's Valdoxan has emerged as the most promising pipeline depression drug following failure of several late-stage candidates. Prescribing for depression patients suffering from comorbid sleep disorders will drive sales over the forecast period.
Datamonitor forecasts moderate uptake of saredutant in refractory depression patients as an add-on therapy. While the drug failed to show efficacy as a monotherapy in clinical trials published over the last year, Sanofi-aventis is continuing to develop saredutant with two add-on therapy trials ongoing.Quantify the current size of the global major depressive disorder marketAssess the impact of recent and anticipated events (patent expiries, new product launches, regulatory approval) on depression-specific brand salesUnderstand the country-specific impact of key events in the major depressive disorder market during the forecast period 2008 to 2017 |
|
| Narcolepsy is a chronic sleep disorder, which affects fewer than 500,000 sufferers across the seven major markets (7MM). The narcolepsy market value has grown considerably since 2004 to reach $230m in 2007 driven largely by the significant penetration of Provigil (modafinil; Cephalon) and Xyrem (sodium oxybate; Jazz Pharma) and the associated increase in the awareness of the disorder.Patient Patient potential including disease definition, etiology, prevalence, diagnosis, and treatment guideline review.Review of the key unmet needs in the treatment of narcolepsy as identified by key opinion leaders interviewed for the report.Analysis of narcolepsy market IMS sales data from 2004 to 2007 for major marketed narcolepsy drugs: Provigil and Xyrem.Pipeline analysis with detailed profile for Nuvigil (armodafinil, Cephalon) and the theory behind potential label expansions beyond narcolepsy.Although generic versions of Cephalon's market leading treatment, Provigil (modafinil), are expected to launch in 2012, Datamonitor expects Cephalon to retain a significant position in the narcolepsy market by switching patients over from Provigil to its follow-up product, Nuvigil (armodafinil).
Despite Xyrem's (sodium oxybate) proven efficacy and its broader narcolepsy coverage than Provigil, Xyrem's sales continue to be limited because of its black box warning, restricted distribution and comparatively high price.
Targeting narcolepsy as a primary indication and then expanding Provigil's label coverage to other sleep disorders has proven commercially successful for Cephalon. Datamonitor believes companies could take this strategy a step further by using narcolepsy as an entry point to access the broader fatigue- or sleepiness-associated market.Quantify the narcolepsy market value in the US, 5EU and Japan and identify the drivers and resistors in this market.Understand key opinion leader (KOL) views on topical issues in the current and future treatment of narcolepsy and associated disorders.Appreciate the potential of off-label prescribing and indication expansions for treatments possessing narcolepsy as the primary indication. |
|
| The transplant immunosuppressant market has seen considerable growth in recent years, but this is expected to slow down. Two factors combine to cause a decline in the market from 2011, the limited availability of donor organs and patent expiries of several key products. Neither the shift to once-daily formulations nor the launch of novel biologic therapies will prevent the contraction.Forecasts for immunosuppressants used in solid organ transplantation and significant pipeline drugs (to 2017 in report and to 2018 in excel tool)Market overview by geographical area, including a rest of the world snapshot and a case study on the Canadian transplant marketFuture market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch datesAn overview of key companies active in the transplant market and their strategiesDatamonitor expects immunosuppressant sales in the seven major markets to grow to about $4.7 billion annually by 2011, after which the market is forecast to slowly decline to $4.4 billion by 2017 due to key products' patent expiries. The immunosuppressant market overall will be held back by the limited availability of organs.
Bristol-Myers Squibb's once-monthly monoclonal belatacept is expected to be the top-selling single brand in the seven major markets in 2017. However, the combined sales of Astellas's tacrolimus franchise (Prograf and once-daily Advagraf) will dominate the immunosuppressant market over the next ten years.
The toxicity associated with calcineurin inhibitors will lead to more emphasis on immunosuppressive regimens that permit reduction or avoidance of products from this class while maintaining adequate immunosuppression and graft survival. This leads to a fertile environment for novel immunomodulatory approaches.Identify key opportunities and threats that will impact the use and uptake of new and existing productsQuantify the future size and scope of the transplant immunosuppressant market and predict the performance of key compoundsUnderstand and capitalize on clinical unmet needs in the market through both lifecycle management of marketed drugs and new product development |
|
| The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017.An overview of the current Hepatitis C market and its key playersIn-depth analysis of Phase II and III clinical development compounds and comprehensive overview of Phase I drugsEpidemiological dynamics of Hepatitis C in the six major markets are discussed along with unmet needs10 year sales forecasts for marketed and six pipeline drugsGiven its large patient potential and significant unmet needs, the Hepatitis C market has attracted considerable interest from companies with a strong presence in infectious diseases. The HCV pipeline is therefore very active and consists of drugs with various mechanisms of action.
Several strategies are being explored in clinical trials, including add-on therapy to the current standard of care, interferon replacement and ribavirin replacement. Of these Datamonitor believes that add-on therapy will be the most successful in the medium term.
The two most advanced pipeline candidates are Schering Plough's boceprevir and Vertex's telaprevir. Both drugs have demonstrated comparable efficacy benefits when combined with current standard of care. Datamonitor expects telaprevir to gain higher market share due to its ability to cut short the overall duration of therapy in genotype 1 patients.Understand current and future Hepatitis C market dynamicsGain insight into the unmet needs of HCV patients and the extent to which pipeline drugs are addressing these issuesEvaluate the Hepatitis C market forecast for existing and key pipeline drugs to 2018 |
|
| Led by the seven triptan brands and Topamax's (topiramate; Johnson & Johnson) continued uptake, seven major market migraine revenues grew strongly at an annual rate of 12.6% to total $4.1 billion in 2007.This report gives a strategic analysis of the likely impact that recent events will have on the future migraine marketIncludes migraine-specific sales forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2017Provides a global market snapshot by including migraine-specific sales analysis for leading brands outside the seven major marketsKey conclusions are supported by key opinion leader commentA 3-month direct-to-consumer (DTC) advertisement review process delayed print and televised branded marketing campaigns for Treximet until late September 2008. As a result, early awareness of Treximet was crucially limited and so Datamonitor has marginally downgraded its forecast.
With continued key opinion leaders enthusiasm and promising Phase III comparator trial results, demonstrating a similar efficacy profile to AstraZeneca's Zomig (zolmitriptan 5mg) and a potentially improved side-effect profile, Datamonitor has upgraded its migraine-specific sales forecast for Merck & Co's telcagepant.
Datamonitor has considerably upgraded its migraine-specific sales forecast of Botox (botulinum toxin Type-A, Allergan). This is due to a greater than previously expected dosing regimen and Ipsen no longer assumed to be seeking a migraine label for its botulinum toxin brand Dysport, reducing future market competition.Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2008 to 2017Quantify the current size of the seven major markets and the trends in the rest of the worldAssess the impact of events, such as patent expiries and new product launches, on the migraine-specific sales of key brand name products |
|
| Over 11.5 million women suffer from infertility in the seven major markets. Although prevalence rates are stable, the trend towards later parenthood is inducing an increasing demand for infertility treatments. As cost of therapy is the major barrier access, the raise in demand puts increased pressure on healthcare payers to reimburse these treatments across the seven major markets.Patient segmentation including detailed etiology of female and male infertility.Analysis of presentation, diagnosis, and treatment trends as well patient referral pathways in each of the major regions.In vitro fertilization treatment trends split by therapy protocol type, treatment regimen and drug class prescribed. Detailed IVF treatment outcomes.Prescriber scoring of key drug brands on factors including efficacy, side effects, dosing flexibility, formulations, patient compliance, and cost.Prescribers perceive available IVF drugs are largely undifferentiated from each other. This allows physicians to prescribe according to personal preference and convenience, which means companies need to build strong relationships with physicians to increase brand loyalty.
Companies with urinary products need to strongly compete on a lower cost profile by lobbing with IVF payers and need to guarantee supply reliability. In Japan, where physicians prescribe 56% of follicle stimulating hormone and 80% of human chorionic gonadotropins in their urinary forms there is a clear opportunity for urinary companies.
The low scoring of Pergoveris (follitropin-alpha and luveris-alpha, Merck Serono) and Org36286 (corifollitropin-alpha, Organon) by survey respondents suggests that there is limited commercial potential for straightforward reformulations of existing drugs. There is a greater need for oral formulations.Target physicians more effectively through an understanding of prescribing behavior and its influences.Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products.Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies. |
|
| Technology markets are changing fast. This brief is essential reading for you to identify the key forces shaping the prospects for your business. In this piece, Datamonitor's analyst specializing in healthcare technology will outline the changes in your market, explain which trends will have the biggest impact and highlight who will benefit from the developments in healthcare technology.An overview of challenges facing healthcare organizations in 2009Datamonitor's view of the technology priorities of providers and payersStrategies to help vendors in the healthcare technology marketThe healthcare industry is not immune to the global economic downturn
Governments are putting their money where their mouth is when it comes to quality of care
US stakeholders are eagerly awaiting Obama's plans for healthcare and healthcare ITLearn about the top trends in healthcare in 2009Gain insight into the technology areas healthcare organizations are investing inIdentify strategies for expanding business opportunities in healthcare |
|
| Based on generics use, the seven major markets may be divided into mature (the US, Germany and the UK) and immature (France, Italy, Spain and Japan) markets, both of which present different challenges, making the fast-growing, high-value emerging markets a tantalizing prospect. In addition to market expansion, acquisition and closer innovator ties represent key strategies for industry growth.An overview of key events which have impacted on the generics industry in the seven major markets.An insight into the strategic trends employed by the industry to sustain growth in an increasingly competitive environment.An introduction to the emerging markets, as the next frontier for industry growth.An outline of how recent M&A activity has altered the generics industry landscape.The global generics market is growing, however it will be the immature and emerging generics markets which will increasingly drive growth, as competitive pressures in the more mature markets intensify, and make sustaining revenue growth more difficult here.
Consolidation continues to be a crucial strategy for generics industry growth, with recent M&A activity having reinforced the position of some companies, whilst bolstering the ranking of others. The magnitude of acquisitions has also increased, and given current economic conditions, such high price-tags may not be sustainable.
The increasingly close relationship between generics and branded companiesfeared by regulators to delay generics market entry in some caseshas reached an extreme in the recent acquisitions of generics companies by innovators, a response to the pressures the latter are under.Identify the issues are impacting on the generics industry in the seven major markets.Understand why the emerging markets are increasingly a target for generics companies.Identify the key strategic trends for the generics industry in the future. |
|
| An effective DTC strategy can catapult a drug into blockbuster status. However, after a 10 year period of skyrocketing DTC budgets, Pharma is now opting for lower cost and more targeted approaches. Pharma faces tighter DTC regulations in the US, while in Europe there may be suggestions that DTC will be employed, but is this likely to work given the differences in culture and market?Analysis of a return on investment model for DTC advertisingCase study analysis of DTC and disease awareness adsOverview of DTC regulation in the USOverview of patient communication for prescription drugs in EuropeThe more serious a disease, the more life threatening it is for the patient, as a result the patient is more empowered as it is keen to find out new potential treatments for the life-threatening condition. In this case, targeted media such as online tools are more suited as they can provide an educational platform and a great source of information.
If a drug is the only one on the market, unbranded advertising is good to raise awarenessfor example Lyrica adopted this strategy as it was first-to-marketin cases such as these, diagnosis is the limiting stage so unbranded advertising is beneficial to leverage this hurdle.
In the absence of direct DTC advertising, information provided online is of paramount importance. The strategic value of online tools for Europe is second to none: although traditional media can increase disease awareness to a wide audience, the internet can provide information to keen consumers.Utilize a return on investment model for a DTC advertising to understand how to make a campaign a successIdentify the differences between advertising regulations in the US and Europe, and what changes are likely to happen in the near futureUnderstand if recent DTC or disease awareness campaigns have been successful, and if not, why not |
|
| CLL is the most common form of leukemia in western countries. Recent therapeutic advances have improved the rate and duration of remission, although there is no consensus over the optimum regimen. CML has a lower incidence than CLL, but is a commercially lucrative indication for Gleevec (imatinib; Novartis) which continues to enjoy blockbuster success, having revolutionized the treatment of CML.Analysis of CLL and CML market based on a survey of 180 chronic leukemia specialists, supported by interviews carried out with key opinion leadersSegmentation of CLL and CML population by disease stage at presentation and proportion receiving anti-cancer therapyIn-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for CLL and CML by line of therapy and disease stageRanking of key prescribing influences in CLL and CML, brand assessment of existing drug therapies, unmet needs and late-phase pipeline overviewRituxan (rituximab; Biogen Idec/Genentech/Roche/Zenyaku Kogyo) has received considerable off-label use for chronic lymphocytic leukemia (CLL), particularly in the US. Positive Phase III data are likely to drive increased uptake in the EU. Conversely, several factors have restricted uptake of Campath (alemtuzumab; Takeda/Genzyme/Bayer Schering).
Gleevec is firmly established as the standard-of-care for newly diagnosed chronic phase CML, while the second generation tyrosine kinase inhibitors Sprycel (dasatinib; Bristol-Myers Squibb) and Tasigna (nilotinib; Novartis) are experiencing increasing uptake in Gleevec-resistant and accelerated phase patients.
Sprycel currently commands a higher market share than Tasigna for CML, benefiting from its first-to-market advantage. However, physicians' perceptions of Sprycel and Tasigna show little differentiation, and there will be close competition for market share in the coming years.Understand prescribing trends and identify key factors that influence treatment choices in CLL and CMLExamine unmet need within the CLL and CML markets and identify opportunities for new product developmentEnhance commercial positioning by increasing understanding of current dynamics within the CLL and CML markets |
|
| Restless legs syndrome (RLS) is a neurological condition, which affects 15.5 million medically significant sufferers across the seven major markets (7MM). Through Requip (ropinirole) and Mirapex's (pramipexole) regulatory approvals in 200506, GlaxoSmithKline and Boehringer Ingelheim pioneered the on-label RLS market, which reached $588m in 2007 across the 7MM.Patient potential including disease definition, etiology, patient segmentation, prevalence, presentation, diagnosis, and treatment guideline review.Review of the key unmet needs in the treatment of restless legs syndrome as identified by key opinion leaders for the report.Analysis of the RLS market IMS sales data from 2004 to 2007 for major on- and off-label marketed restless legs syndrome drugs.Pipeline analysis with detailed profiles for key late-stage drugs: Neupro (rotigotine patch), Nenad (lisuride patch), Solzira (gabapentin enacarbil).Inappropriate pharmacokinetic properties may limit the development of oral extended-release versions of the current oral brands for restless legs syndrome, and prevent off-label prescribing of formulations designed with optimal pharmacokinetics for Parkinson's disease.
Drugs acting with a different mechanism and inducing no augmentation could become beneficial alternatives to current dopamine agonists. Datamonitor expects Solzira to become a leading brand in the future market as specialists and primary care physicians may be more confident to prescribe it to a larger population and particularly to mild patients.
Drugs with new delivery methods could be helpful for RLS patients and prove commercially successful. While formulations with a long duration of action (e.g. UCB's Neupro) may be beneficial for severe patients, treatments with rapid onset of action (e.g. UCB's rotigotine nasal spray) could be used as rescue therapy in moderate-to-severe patients.Quantify the RLS market value in the US, 5EU and Japan and identify the drivers and resistors for RLS treatments.Understand key opinion leader (KOL) views on topical issues in the current and future treatment of RLS symptoms.Explore the R&D pipeline for RLS and the future directions of the market as identified by interviewed KOLs. |
|
| Despite forming the mainstay of pharmacological treatment of anxiety disorders, response rates to serotonergic-based treatments are often less than robust. As such, physicians are increasingly looking towards novel drugs. For pharmaceutical companies, the pressure to meet this need and maintain market share is growing as the patent expiries of three major brands draws near.Analysis of key marketed brands and late-stage pipeline drugs.Anxiety disorders-specific drug sales volume and value forecasts to 2017 in the US, Japan, and five major European markets.Identification of future market events that are expected to affect anxiety disorders drug revenues.Analysis of patient potential, unmet needs and clinical trial design in anxiety disorder.Atypical antipsychotics are expected to change the landscape of the future anxiety disorders market, with Seroquel XR set to benefit from first-to-market status upon approval in generalized anxiety disorder. Seroquel XR will be positioned as a second/third-line treatment for patients who have failed to respond to available antidepressants.
In view of the high co-morbidity between anxiety and depression, it remains in the interests of antidepressant manufacturers to maximize the patient potential of their products. However, with three key brands set to experience patent expiration over the forecast period (20082017), competition within the antidepressant drug classes will intensify.
The presence of neurokinin (NK) receptor antagonists and corticotrophin releasing factor (CRF) antagonists in the anxiety disorders pipeline have generated much interest among interviewed key opinion leaders. Datamonitor regards NK receptor antagonists as holding the greatest promise in the treatment of anxiety disorders.Understand the current anxiety disorder market dynamics and how they are expected to evolve out to 2017.Benchmark key late-stage pipeline anxiety disorder compounds against the current market leading brands.Understand unmet needs in the anxiety disorders market based on key opinion leader comments. |
|
| This report analyzes the emerging sector of molecular diagnostics. It provides a clear classification, assessing the leading technologies and key tests which are positioned in this exciting area of diagnostics. The current MDx market size and leading players are analyzed, with a market forecast of the MDx segment as well as the total in vitro diagnostic (IVD) market from 2007-13 also providedA definitive classification system for in vitro diagnostics (IVD) and molecular diagnostics (MDx), and the differing regulatory pathways in the US/EUMarket size and forecast growth rates to 2013 for IVD and MDx segmentsA detailed analysis of emerging 'companion diagnostics' (the synergy of targeted prescription therapies with diagnostics)A database detailing c.120 MDx products on the marketThe MDx market is a small but fast growing segment of the global IVD market, with an estimated 2007-13 CAGR of 14.0%. Total MDx sales are expected to outpace the total IVD market (2007-13 CAGR of 5.0%) over the next six years
Of particular interest is the role of MDx in companion diagnostics (the synergy between targeted prescription pharmaceuticals and molecular diagnostic tests). Datamonitor has identified seven key therapeutics and more than 12 MDx tests which exemplify this marriage
The report also details a MDx database containing more than 120 MDx tests. The key tests are positioned in the therapy areas of infectious diseases, hematology and oncology by key MDx players such as Roche Diagnostics, Gen-Probe, Abbott Molecular and MyriadCompare the differing growth dynamics of the MDx segment and that of the wider IVD marketAssess the potential of 'companion diagnostics' and its role in influencing physician selection of molecular targeted therapiesIdentify the key diagnostic tests and players in the MDx segment |
|
| Lupus is a chronic, autoimmune disorder, characterized by unpredictable flares and remissions. Affected areas can include the joints, skin, kidneys, heart, lungs, blood vessels and the brain. There are currently only three medications approved for the treatment of lupus; hydroxychloroquine, aspirin, and prednisone, highlighting the significant unmet need.Analysis of the lupus market based on a survey of 180 rheumatologists supported by key opinion leader interviewsDetailed overview of epidemiology in lupus benchmarked against physician perceptionPatient segmentation by both disease severity and organ involvement (multiple organ disease, skin, joints, blood, CNS, and kidney)Assessment of treatment trends and outcome measuresRheumatologists provide the long-term management for two-thirds of lupus patients. 40% of patients present to a primary care physician, and most are referred to a rheumatologist for diagnosis. Long-term care is also linked to the major organ involved, for example 10% of patients receive long term management from a nephrologist.
The development of effective, steroid-sparing therapies is the highest priority for pharmaceutical companies to address. Biologics will play a prominent therapeutic role over the next few years. Current biologic use by involvement varies between 2% and 10%, whilst steroid uptake varies between 37% and 69%.
Four major indices are predominantly used, creating a hindrance to the application of clinical trial data, and one third of rheumatologists actually use more than one index in clinical practice. The extent of organ damage was considered the most important issue of disease activity assessment, followed by antibody and inflammatory marker levels.Gain competitive advantage with one of the most extensive primary research reports available in lupus, with data from 180 prescribing rheumatologistsIdentify with prescribers more effectively, through an understanding of referral patterns based on data-rich treatment numbersValidate new product forecasting based on diagnosis rates and treatment by patient segmentation and drug therapy class |
|
| The overall incidence of bladder cancer in the seven major markets is forecast to exceed 160,000 by the end of 2008. Treatment of bladder cancer employs mainly immunotherapy and chemotherapy. However, both these methods are ineffective in improving long-term survival. Thus, there is a lucrative commercial opportunity for drug developers to enter this market, especially in the metastatic setting.Current diagnosis and treatment of bladder cancer, including treatment regimens by stage and geographical locationIssues in diagnosis, treatment strategies and unmet needsExamination of pipeline activity and potential future opportunities for drug developersStakeholder opinions based on qualitative interviews with five opinion leaders from the US and EuropeDiscovery of more effective systemic therapies is crucial for the treatment of patients with advanced or metastatic disease as current therapies have little impact on survival.
BCG therapy, the current standard treatment for non-invasive bladder cancer has limited use in patients who experience multiple recurrences. Patients who become refractory or intolerant to further BCG treatment have few options. There is therefore a large patient potential for drugs that can replace BCG or treat BCG-refractory patients.
Bladder cancer therapy consists of cytotoxics and immunotherapy agents that have been genericized for many years. Late-stage pipeline drugs consist of targeted therapies and cytotoxics including Urocidin and EOquin. Some late stage drugs have demonstrated favourable efficacy in trials and look to fill some of the unmet needs in bladder cancer.Understand the pathology and epidemiology of bladder cancerUnderstand the limitations of current bladder cancer treatmentObtain insight into the commercial opportunities available in the bladder cancer market |
|
| The myasthenia gravis market is set to grow from $44m in 2007 to $239m in 2017 across the seven major pharmaceutical markets in Datamonitor's base scenario forecast. Amarin's pipeline candidate EN101 is forecast to become the market leading brand with sales of $153m in 2017.Scenario based analysis and forecasts of the commercial potential of the myasthenia gravis market to 2017.Analysis of the patient potential, commercial viability, and unmet needs of the myasthenia gravis market.Indication-specific sales forecasts of marketed and pipeline drugs to 2017.Assessment of the treatment algorithms used in this disease.Although myasthenia gravis is an uncommon disease (106,000 patients across the seven major markets), it is more prevalent than Huntington's disease or amyotrophic lateral sclerosis (31,000 and 34,000 patients, respectively), both orphan neurological diseases with larger late-stage pipelines.
In the majority of patients, symptoms can be well controlled with current treatments. However, very poor side-effect profiles and inconvenient dosing regimens of these therapies impact on the patient's quality of life, and represent key unmet needs in myasthenia gravis treatment.
Amarin's EN101 is forecast to become the market leading brand with sales of $153m in 2017 in Datamonitor's base scenario. In an alternative scenario EN101 proves to be steroid sparing enhancing its commercial potential ($621m in 2017). However, poor bioavailability of RNA therapies enhances the risk of EN101 failing in larger scale trials.Access the lucrative potential of this underdeveloped neurological auto-immune disease.Benchmark key late-stage compounds against current leading therapies.Understand the opportunities in this market based on the comments of interviewed key opinion leaders. |
|
| Prevalence of diabetic renal disease is on the rise. Current treatment focuses on the management of hypertension and glycemic control, but is unable to address the deterioration of renal function. An unmet need exists for therapies fully reversing disease progression. Early diagnosis can help to prevent the disease progression but lack of early diagnostic markers makes this option rather remote.What are the current definitions, pathophysiological stages and the natural history of progression of diabetic renal disease?What are the currently available diagnostic methods, the issues and the unmet needs in diagnosis and early detection of diabetic renal disease?What are the available treatment approaches in the early stages of diabetic renal disease, the unmet needs and the future trends?What are the treatment options in advanced stages of diabetic renal disease and the changing role of renal dialysis and kidney transplantation?Diabetic nephropathy, which is one of the most serious complications of diabetes, develops in approximately 50% of patients with type 1 diabetes mellitus who have had diabetes for 20 years. Although it is less prevalent in type 2 diabetes, clinically significant renal disease still develops in 1520% of type 2 diabetes individuals.
Most diabetic renal disease patients are suffering from type 2 diabetes, and are therefore diagnosed late once the disease has already reached its advanced, irreversible stages. This highlights one of the major issues in diabetic renal disease: the need for early diagnosis and good diagnostic markers and risk scores.
The only available treatment in advanced stages of diabetic renal disease is renal replacement therapy. Dialysis comes at a high cost and significantly reduces the patient's quality of life. Hence, it is clear that the main focus of clinicians is on the prevention of disease progression through stringent glycemic and blood pressure control.Understand current definitions, diagnostic methods and treatment approaches in diabetic renal diseaseCurrent challenges and future opportunities in diabetic renal disease managementDifferences, advantages and disadvantages of pharmacological and non-pharmacological disease management |
|
| RNA therapies have been in development for a number of years, but are yet to achieve any notable commercial success. Improvements have been made following initial attempts and the technology may finally be coming to fruition.Strategic review of the different RNA therapy technology offeringsAssessment of the commercial potential of key productsAnalysis of the RNA therapy pipeline according to key metricsGuidance on the factors that dictate RNA therapy design and the markets best suited to offer returnsWith the loss of patent protection on maturing blockbusters, innovative new products are required if the pharmaceutical industry is to maintain sales. RNA therapy potentially provides a rich source of such products, allowing targets that are not 'druggable' by other technologies to be exploited.
Despite a number of attempts, only one RNA therapy has reached the market. However, new mechanisms such as RNA interference have given rise to a generation of pipeline candidates characterized by improved safety and efficacy.
While sales on the scale of those enjoyed by monoclonal antibodies seem a way off, evidence suggests RNA therapy is now on course to deliver commercial returns.Assess the 134 RNA therapies in preclinical development and beyondUnderstand how RNA therapies fit alongside small molecule drugs, therapeutic proteins and monoclonal antibodiesUnderstand reasons for the lack of approvals to date and how to maximize chances of commercial success |
|
| Datamonitor expects the antidiabetics market to reach $29 billion, across the seven major markets, by 2017. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, and large growth in patient numbers. However, patent expiries of the glitazone (TZDs) class will restrain market growth.Description of the competitive landscape in antidiabetics across seven major markets with market definition and overview.Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.Analysis of major events and brand dynamics affecting the diabetes market.The antidiabetics market in the seven major markets is expected to grow from $18 billion in 2007 to $29 billion in 2017 at a rate of 5% CAGR. Significant unmet needs remain in diabetes fueling a large pipeline. The epidemiological growth of the market, driven by the obesity epidemic and improved diagnosis rates, is further driving the market.
The glitazone class was the major non-insulin antidiabetic therapy in 2007 driven by the Actos and Avandia franchises. Both of these drugs will lose their marketing leading positions following patent expiry in 2011 and 2013. Safety concerns over Avandia remain unresolved and the drug will continue to continue to lose market share.
The incretin mimetics are likely to be the beneficiaries of Avandia's problems and the DPP-IV inhibitors are expected to become the leading non-insulin antidiabetics. GLP-1 agonists are also expected to record significant sales. The two classes will provide over 75% of the sales from newly launched antidiabetics.Quantify the future size of the antidiabetics market and identify opportunities for new products.Learn how product expiries will shape the antidiabetics market.Understand the barriers to uptake for novel antidiabetic agents, and the implications of recent regulatory reviews. |
|
| The mature pain market has experienced a turbulent 4-year period during which the estimated seven major market sales value has fallen from an all-time high in 2004 down to $24.29 billion in 2007. However, through the growing use of non-traditional analgesics and the emergence of a number of opioid reformulations, the market is set to consolidate in a new phase of growth and prosperity.Analysis of 200407 prescriptions for ATC classes M1A, N1A, N1B, N2A, N2B and non-traditional analgesics split by region, class, and delivery methodFuture market assessment, including pain market forecast by region and class level through to 2017Brand dynamics assessment, including the current competitive landscape, marketing strategies employed, and focus on leading brands within each classStrategic analysis of key players in the pain market and focus of corporate strategic trends and recent licensing dealsBetween 2004 and 2005, the seven major market pain market moved from a brand dominated market to one where unbranded products account for the majority of sales value. This trend strengthened over the last 2 years, with major genericization of the N2A narcotic analgesic and N2B non-narcotic analgesic classes creating this financially-driven shift.
After 2 consecutive years of declining sales, 200607 saw positive market growth of 8.7%. The pain market is forecast to continue this annual growth through to 2011 to be worth approximately $31.5 billion, driven by non-traditional analgesic brand sales for neuropathic pain and fibromyalgia.
In contrast to Pfizer's focus on in-house R&D, Johnson & Johnson has turned to collaborations with specialist companies to bolster its previously lackluster pain pipeline. Additionally, smaller pain companies are increasingly collaborating to combine drug development capabilities with commercial expertise in order to bring new products to market.Identify and understand the commercial characteristics of the pain market across the US, Japan, 5EU, and rest of world marketsUnderstand the future pain market landscape to align R&D decisions and target the indications that offer the most opportunity to your companyQuantify the key historical company and brand dynamics that have shaped the pain market |
|
| Datamonitor expects incretin mimetics to emerge as a major new therapeutic class in non-insulin antidiabetics, driven by an explosion in the patient population, safety fears surrounding established therapies and significant unmet patient needs.Comprehensive analysis of the current non-insulin antidiabetic pipeline detailing the broad range of developmental classes. A detailed clinical and commercial assessment of all key emerging therapies.Sales based sales forecasts for key late-stage developmental non-insulin antidiabetics agents in the seven major markets to 2017.Incretin mimetics, GLP-1 agonists and DPP-IV inhibitors, are likely to be the most successful candidates in the pipeline. Pipeline incretin candidates are forecast to generate sales of $7,905m in the seven major markets in 2017
A huge number of molecules are in development as non-insulin antidiabetics to meet the increase in patient population and disease unmet needs. 137 candidates from 60 different mechanisms of action are in development
Big Pharma dominate the non-insulin antidiabetic pipeline as the disease is one of the few growth areas in the cardiovascular and metabolic disease areas. Sixteen of the top twenty drug companies have a non-insulin antidiabetic pipeline and between them are developing 52% of the pipelineQuantify the future drugs in the non-insulin antidiabetic market.Identify licensing opportunities based on company portfolio and market needs.Assess the remaining market opportunity, where established therapies and other developmental compounds fail to address key unmet clinical needs. |
|
| M&As have been the preferred growth strategy by a majority of Pharma companies. Although mega-mergers certainly create economies of scale and boost pipelines, the long-term effects may not be as favorable as desired. Current trends show the mega-mergers of the past are now a long gone strategy, as now companies are seeking to buy smaller companies for a smaller fee.Overview of the main trends driving M&A activityAnalysis of key transactions in the past and the current state of the new companyCase study analysis of recent M&A deals for each key trendMonoclonal antibodies have been a driving force of M&A activity within the biotech sector. Monoclonal antibodies make biotechs a very alluring target as they are predicted to have strong growth, and are not subject to generic erosion in the immediate future. Such is their pulling power that they have commanded high deal values and premiums.
The only country which has seen an increase in M&A activity is Japan. Aided by the weak dollar, Japanese firms are keen to enter the lucrative US market. In just over six months there have been four major buy-outs by Japanese companies.
Due to fierce competition and saturation in the US, coupled with a strengthening Indian market, India's generics companies have become more acquirers than targets, either buying directly in the US or indirectly by acquiring a less costly European firm.Identify the key trends driving M&A activityUnderstand the strategic motivations behind major dealsGain insight as to whether these trends are likely to continue in the future |
|
| The antidyslipidemic market is increasingly governed by cost concerns which appear to be more pressing than the safety and efficacy concerns. Cost-saving initiatives together with the continuing genericization are going to bring the antidyslipidemic revenues down by 25% from $26.6 billion in 2007 to $19.9 billion in 2017.Description of the competitive landscape in antidyslipidemics market with detailed overview of main challenges for launched and novel agents.Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.Analysis of major events and brand dynamics affecting the antidyslipidemics market, including the overview of the pipeline drugs.The patent expiry of Zocor in 2006 in the US steepened the drastic revenue fall. With Lipitor losing its patent protection within the next five years, the market is expected to shrink further to $19.9bln by 2017 and become even harder to enter. In strong relation to this is Pfizer's decision to exit the CV development.
The US FDA has been becoming ever more conservative over the recent years. Its recent tightening of the approval process has resulted in the non-approval of Cordaptive (Tredaptive) in the US. This is the first time in the history of antidyslipidemic development that a drug approval may be delayed until the outcome data are available.
The current late-stage pipeline offers a number of SPCs, which is an eloquent marker of a certain degree of stagnation in the development of novel agents, as it is now associated with more risks than before, due to the torcetrapib's failure in 2006, as well as the non-approval of Cordaptive in the US this year.Quantify the future size and understand the background of the antidyslipidemic marketQuantify the impact of the recent ENHANCE results on the dynamics of the marketSize up the potential for the market expansion and revenue increases that recent guidelines, initiatives and regulatory changes may bring. |
|
| The ability to exchange information between healthcare stakeholders is necessary to improve quality of care and decrease healthcare costs, but achieving interoperability in healthcare has long been an elusive goal. Today, however, interoperability is already a reality in some healthcare settings. These early successes are paving the way for more health information exchange (HIE) in the future.Identifies the key barriers to interoperabilityProvides examples of successful HIEsAnalyzes the role of personal health records in HIEMore patient information allows providers to see a 360 degree view of the patient
Organizational issues, not technical ones, are limiting the growth of HIE
Smaller, underlying networks will connect to build a worldwide HIE networkUnderstand where interoperability is today and where it will be in the near futureAlign product messaging with what will resonate best with healthcare organizationsIdentify strategies that will increase HIE success |
|
| Schizophrenia is a chronic and severe mental health disorder affecting around 4.6 million schizophrenia sufferers across the seven major markets. Currently led by oral branded atypical antipsychotics, the schizophrenia market will undergo some big changes over the period 20082017. Prospective players can expect to face stiff competition from generic versions of all currently branded drugs.Analysis of key marketed brands and late-stage pipeline drugs.Schizophrenia-specific drug sales volume and value forecasts to 2017 in the US, Japan, and five major European markets.Identification of future market events that are expected to affect schizophrenia drug revenues.Analysis of patient potential, unmet needs and clinical trial design in schizophrenia.The schizophrenia market is anticipated to grow slowly until 2011 to reach $4.3 billion across the 7MM. Despite the launch of a few pipeline drugs, the market will decline thereafter owing to the widespread launch of generic risperidone by the end of 2008, followed by generic versions of all currently marketed schizophrenia drugs from 2011 onwards.
The increasing uptake of long-acting injectable (depot) atypical antipsychotics is expected to partially alleviate the branded schizophrenia sales decline. Positive effects on patient compliance will stimulate sales of these formulations which are forecast to reach a combined value of $1.2 billion by 2013.
The schizophrenia late-stage pipeline lacks innovation. Sales of most oral investigational drugs will be limited by extensive generic competition across the 7MM. However, drugs with novel mechanism of action could prove commercially successful, demanding a price premium and offering alternative treatments for refractory patients.Understand the current schizophrenia market dynamics and how they are expected to evolve out to 2017.Benchmark key late-stage pipeline schizophrenia compounds against the current market leading brands.Understand unmet needs and opportunities in the schizophrenia market based on key opinion leader comments. |
|
| Rapid economic growth on the back of a strong export drive has contributed to making South Korea one of the largest markets in Asia, after Japan, China and India. The country's pharmaceutical market is beginning to open up to multinationals, a trend set to gather momentum as regulatory and IP changes take hold, potentially putting the domestic industry under threat.An economic, social, political and demographic overview of South Korea, and likely changes to the current market climate.An overview South Korea's healthcare system, providing an outline of its establishment, funding and outlook.An overview of disease prevalence in South Korea, and how this translates into pharmaceutical use.An insight into the major companies operating in South Korea, and how this will change in the future.South Korea's large, growing pharmaceutical market is due to undergo major change as a result of a Free Trade agreement signed with the US. The formerly domestic generics-dominated market could be flooded with more expensive imports, a welcome outcome for multinationals who have historically found South Korea to be a difficult market to penetrate.
Healthcare spend in South Korea has thus far been low, due in part to the large out-of-pocket contribution required from the patient, which limits demand. The increasingly elderly nature of the population going forward however, will push expenditure up, with the result that public spending is set to grow.
Due to South Korea's rapid industrialization, the incidence of acute communicable disease has fallen in counterpoint to the rise in non-communicable disease, with the result that cardiovascular disease is one of the leading causes of death, and half of the top 10 retail drugs in South Korea fall into this class.Understand how South Korea has become one of the largest markets in Asia, and why it is increasingly a target for multinationals.Gain an insight into how healthcare in the country works, and how it is likely to change in the future.Identify who the key player are, and how market changes are likely to impact on them. |
|
| Almost 100 million post-menopausal women suffer from osteopenia and osteoporosis in the seven major markets. Those diagnosed are often identified through screening for low bone mineral density or after presenting with a fracture. Although not all guidelines are clear on when to initiate pharmacological treatment, most base their assessment of the type of drug to treat with on cost-benefit analysesPatient segmentation by disease severity as defined by the WHO; including osteopenia, osteoporosis, and severe/established osteoporosisAnalysis of presentation, diagnosis, and treatment trends as well patient referral pathways in each of the major regionsTreatment trends split by line of therapy and disease severities, including drug switching behaviors in each of the seven major market regionsPrescriber scoring of key drug brands on factors including efficacy, side effects, dosing flexibility, formulations, patient compliance, and costThe asymptomatic characteristics of osteoporosis, the fact that the majority of fractures remain undetected and the lack of nationwide screening means that osteoporosis is severely under-diagnosed.
About two-thirds of the patients are treated initially by a specialist and stay with the specialist for long-term treatment across the seven major markets, although a small group of patients switch from initial treatment by a specialist to long-term treatment under their general practitioner
The most important factors that physicians consider when prescribing drugs for osteoporosis are efficacy on bone mineral density and fracture risk reduction. Bisphosphonates reached similar scores on efficacy and safety in Datamonitor's physician survey, but are differentiated in terms of cost, flexibility of administration, and intermittent dosingTarget physicians more effectively through an understanding of prescribing behavior and its influences.Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new productsBenchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies. |
|
| The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiries of the top antidyslipidemic, Pfizer's Lipitor, as well as by the recent negative messages from the ILLUMINATE and ENHANCE clinical trials.Quantify the future size and understand the background of the antidyslipidemic marketUnderstand the commercial landscape in terms of new product potentialUnderstand the barriers to uptake for novel antidyslipidemics. |
|
| The traditional sales force model is no longer effective as doctors are no longer the key prescribing decision makers. Governments and payers are implementing cost cutting initiatives and promoting generic use in an attempt to control escalating healthcare costs. This has made it increasingly difficult for sales representatives to promote expensive branded drugs to doctors.Provides an overview of the current drivers behind the evolution of sales force effectivenessAnalyzes current and emerging sales force effectiveness modelsFocuses on how to optimize sales force effectiveness through a variety of mediumEvaluation of key customer targeting and segmentation strategiesOptimizing sales and marketing resources, and identifying influential stakeholders is critical, as decision making around prescribing choices becomes more complicated following the emergence of additional stakeholders such as government bodies and payers.
Most emerging models appear to be moving from the sales representatives working in silos, to a key account management (KAM) style role; treating local healthcare economies as an account.
eDetailing is becoming an increasingly attractive marketing tool for Pharma. However, pharma companies have been slow to adopt the practice. This is possibly due to the difficulty in measuring ROI and most importantly, the unimaginative format of eDetailing to dateUnderstand why sales force size and structure in the pharmaceutical industry is changingIdentify the opportunities to improve promotion through targeting emerging stakeholdersAssess new sales models that Pharma companies are now implementing to improve sales force effectiveness |
|
| With growing competition, Pharma companies are under increased pressure to deliver additional value for key stakeholders through their portfolios. Companies with comprehensive portfolios offering more to physicians, patients, payers and pharmacists will have the competitive edge.An overview of the current trends in pharmaceutical portfolio managementAnalysis of the ways in which pharmaceutical companies can develop their portfolios to add value to key stakeholdersCase study analysis of recent portfolio challenging scenarios and what strategies were, or could be employed, in such situationsAchieving a balanced portfolio in terms of new product development, lifecycle management and business development and licensing is key to reducing risk and growing franchise sales. With patent expiry of key blockbuster drugs approaching lifecycle management is very popular but over reliance on this approach can damage long-term prospects
Niche and specialty therapies are gaining ground over primary care portfolios, but growing competition and a tougher pricing and reimbursement environment do not make this an easy direction to follow
Payers have greater power than ever, and are increasingly influencing physicians' treatment choices. Therefore, pricing and reimbursement analysis needs to be incorporated into portfolio revision process as early as possible in drug development.Understand the key issues in the pharmaceutical marketplace that are putting a strain on drug portfoliosUnderstand the recent trends in portfolio development strategies and learn from best practiceGain an insight into how pharmaceutical companies are responding to situations that are challenging their marketed and R&D portfolios |
|
| Pharma is experiencing tough times, facing both economic and regulatory pressures, with increasing demands for improved safety data and comparative efficacy studies. Consequently, the duration, size, complexity and ultimately cost of clinical trials is on the increase, while simultaneously, the success of late-stage clinical trials is declining.Overview of current clinical trial trendsStrategic recommendations on how to optimize clinical trial successCase study analysis of clinical trial and regulatory successes and failuresEvaluation of why there are frequently differences in FDA and EMEA approval outcomesIn the increasingly competitive and cost-conscious pharmaceutical environment, it is important that pharma companies develop their pipeline products as quickly and cheaply as possible, while ensuring that they receive marketing approval as well as authorization from the relevant reimbursement agencies.
Approximately 58% of Phase III clinical trials are unsuccessful, with the primary cause for failure being the inability of the trial data to demonstrate efficacy of the tested product against placebo. However, this success rate can be improved by implementing a number of different strategies discussed herein.
Most drugs that apply for approval from the FDA and the EMEA are approved by both agencies. However, a minority of applications are approved by one agency and not the other, for reasons largely based upon the design of clinical trials that form part of the submission package. Find out how to maximize the chance of approval in both markets.Identify clinical trial trends in today's pharmaceutical market, and how this affects productivity and return on investmentUnderstand how a wide range of strategies that can improve clinical trial design and outcome, and identify how these can best be implementedGain insight into how to optimize the clinical trial process and increase the chance of clinical, and ultimately commercial success |
|
| Adjuvants are coming increasingly into focus for vaccine developers since many novel split- and subunit vaccines are insufficiently immunogenic on their own. Adjuvants offer a solution: they can accelerate, enhance and prolong the immune response to vaccination but also enable the use of antigen-sparing formulations. This makes them an attractive option for prophylactic and therapeutic vaccines.In-depth analysis of key TLR-dependent and TLR-independent adjuvant candidates in clinical developmentThorough assessment of key opportunities and risks for novel adjuvantsReview of clinical trials and available data for adjuvants in developmentIn-depth discussion of regulatory hurdles and strategic advice on how to overcome themIn order to overcome the high regulatory barriers, adjuvant developers should focus on indications with high unmet need and no available vaccines. As safety and reactogenicity will be key factors in the FDA's evaluation of novel adjuvants, the barrier to approval of novel adjuvants is lower for therapeutic than for prophylactic indications.
Datamonitor sees combinations of immunostimulatory adjuvants with efficacious delivery systems as a promising approach, but hurdles to approval for these combinations will be higher than for single-component adjuvants. The future regulatory performance of GSK's AS04 will have a crucial impact on the prospects of such combination approaches.
Most available licensed adjuvants, such as alum and MF59, stimulate a strong Th2 response, making them unsuitable for a large number of indications requiring a CTL-mediated immune responses. Novel adjuvants could significantly improve the prospects of vaccine development in indications with a high unmet need, including cancer and tuberculosis.Review profiles and clinical data of key adjuvants both marketed and in clinical development and assess their future potentialGain insight into the current state of the vaccine adjuvant industry and its future chances and challengesUnderstand regulatory hurdles and develop strategies to maximize chances of approval for novel adjuvants |
|
| Stimulated by evidence of disease slowing with Teva/Lundbeck's Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson's disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (20072013), peaking at $3.1 billion in 2013.This report gives a strategic analysis of the likely impact that recent events will have on the future Parkinson's disease marketIncludes Parkinson's disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017Provides a global market snapshot by including Parkinson's disease-specific sales analysis for leading brands outside the seven major marketsKey conclusions are supported by key opinion leader commentDatamonitor has upgraded its forecasts of Teva/Lundbeck's Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the market leading Parkinson's disease drug at this time.
GlaxoSmithKline's Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheim's Mirapex (pramipexole).
Datamonitor has downgraded its sales forecasts of UCB's Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCB's misfortune.Understand the impact of recent and anticipated events on the Parkinson's disease market during the forecast period 2008 to 2017Quantify the current size of the seven major markets and the trends in the rest of the worldAssess the impact of events, such as patent expiries and new product launches, on the Parkinson's disease-specific sales of key brands |
|
| The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiries of the top antidyslipidemic, Pfizer's Lipitor, as well as by the recent negative messages from the ILLUMINATE and ENHANCE clinical trials.Description of the competitive landscape in antidyslipidemics across seven major markets with market definition and overview.Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.Analysis of major events and brand dynamics affecting the antidyslipidemics market.Some 40% of the entire seven major market antidyslipidemic market is commanded by Lipitor, the gold standard therapy and highest selling agent among statins and antidyslipidemics in general. This will change dramatically after the loss of its patent protection in 2010/2011, reducing Lipitor's market share to 9% only by 2017.
The top 10 brands accounted for 81% of the market in 2007; the top revenue generating agents include Lipitor, Vytorin, Crestor, Zetia and Tricor. Over the forecast period the share of the brands in the antidyslipidemic market is expected to fall due to the further genericization.
The recent ENHANCE trial results have added to the distressing effects of genericization, while at the same time curbing the sales of Zetia and Vytorin, and further undermining confidence in the surrogate markers of atherosclerosis. This event is likely to make the ever-stricter process of approval for new agents even harder.Quantify the future size and understand the background of the antidyslipidemic marketUnderstand the commercial landscape in terms of new product potentialUnderstand the barriers to uptake for novel antidyslipidemics. |
|
| Antihormonal therapies are a class of cancer therapeutics that generated branded drug sales of $5.8 billion in the seven major pharmaceutical markets in 2007. However, the relative maturity of the market means that it is has become a highly genericized therapeutic class. Even still, the lack of innovation within this saturated market helps many leading brands retain their success.Analysis of the performance of each of the antihormonal therapy cancer brands in the seven major markets, forecast to 2017Analysis and segmentation of the market at various levels including drug class, indication, company and sales growth rateAssessment of the leading cancer brands and drug classes to identify key success factors within this sectorQuantification of the market size of the antihormonal therapy cancer brands in the seven major pharmaceutical markets with a rest of world snapshotThe antihormonal therapy cancer brands market was worth $5.8 billion in 2007and is forecast to decline in sales to $5.2 billion by 2017. Factors limiting market growth include patent expirations, the increasing entry of generic competitors onto the market and the interchangeable nature of some brands within each class.
As a class, the aromatase inhibitor brands achieved higher sales than the luteinizing hormone-releasing hormone analog, anti-androgen or anti-estrogen brands in 2007, achieving $2.4 billion in the seven major pharmaceutical markets. The success enjoyed by the aromatase inhibitors can be attributed, in part, to their favorable side effect profile.
Thirteen differently sized pharmaceutical companies are involved in the development of currently approved antihormonal therapy cancer brands. AstraZeneca leads market, with five out of the 11 brands and includes the leading aromatase inhibitor brand Arimidex.Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2007 to 2017Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growthBenchmark the antihormonal therapy cancer brands against their generic products and align their 7MM performance with a rest of world snapshot |
|
| Spurred by uptake of Biogen Idec and Elan's Tysabri (natalizumab) and continued revenue growth for the three beta-interferon brands and Teva's Copaxone (glatiramer acetate), the seven major multiple sclerosis market value increased 15.1% from 2006 to $5.3 billion in 2007.This report gives a strategic analysis of the likely impact that recent events will have on the future multiple sclerosis marketIncludes multiple sclerosis-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017Provides a global market snapshot by including multiple sclerosis-specific sales analysis for leading brands outside the seven major marketsKey conclusions are supported by key opinion leader commentDespite the recent confirmation of two new cases of progressive multifocal leukoencephalopathy (PML), with a much stronger 200708 enrollment rate than previously anticipated and a greater level of confidence among opinion leaders, Datamonitor has upgraded its Tysabri's forecast.
Datamonitor remains highly positive on Novartis's FTY720 (fingolimod). FTY720 is expected to achieve the greatest sales of all current late-stage pipeline products. However, sales growth will be restricted from 2012 by the later launch of additional oral pipeline disease-modifiers, which will represent tough direct competition.
Genzyme and Bayer Schering's alemtuzumab (Campath) has been added to this latest multiple sclerosis forecast. Potentially positioned in both the earliest stages of the disease and for rapidly progressing patients refractory on other therapies, a poor perceived safety profile and an assumed low price-point, will limit returns from this market.Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2008 to 2017Quantify the current size of the seven major markets and the trends in the rest of the worldAssess the impact of events, such as patent expiries and new product launches, on the multiple sclerosis-specific sales of key brand name products |
|
| After 3 years of steady growth, the value of the insomnia market across the seven major markets (7MM) slumped by 12% to $4.1 billion in 2007 due to rapid generic erosion of Sanofi-Aventis's market leader Ambien (zolpidem) in the US. However, this downturn will be short-lived and the market will regain growth from 2009 to $6.9 billion in 2017 driven by the launch of new treatments across the 7MM.This report gives a strategic analysis of the likely impact that recent events will have on the future insomnia marketIncludes insomnia-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017This report provides a global market snapshot by including insomnia-specific sales analysis for leading brands outside the seven major marketsKey conclusions are supported by key opinion leader commentDuring 2007, US sales of Ambien CR overtook sales of Lunesta indicating that Sanofi-Aventis' attempt to switch patients from Ambien to Ambien CR has been successful. Ambien CR is forecast to become the market leader in 2017, achieving sales of over $1.5 billion.
Actelion's orexin receptor antagonistalmorexantis forecast to be the main driver of pipeline sales products, contributing blockbuster revenues by 2017. This is higher than previous forecasts due to Actelion's recent commercialization deal with GlaxoSmithKline, which will enable the realization of almorexant's full commercial potential
Neurim and Lundbeck's Circadin (controlled release melatonin) is the most recent entry to the insomnia market in Germany and it is expected that the drug will be rolled out in remaining EU countries later in 2008. Due to an uncompetitive clinical profile Datamonitor forecasts sales of Circadin to be small compared to other leading brandsUnderstand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2007 to 2017Quantify the current size of the seven major markets and the trends in the rest of the worldAssess the impact of events, such as patent expiries and new product launches, on the insomnia-specific sales of key brand name products |
|
| In 2007, HIV drugs achieved sales of $9.3 billion in the 7MM, growing faster than the overall market at a CAGR of 11.3% from 2004-2007. Due to patent expirations, Datamonitor expects the market's growth to slow down somewhat, reaching total sales of $15.1 billion in 2017. Among the ROW, the Canadian HIV market in 2007 was worth $272 million, achieving a CAGR of 24% from 2004-2007.In-depth analysis of the current HIV market across the US, EU, Japan and a ROW snapshotThorough assessment of underlying commercial and clinical factors shaping the antiretroviral marketDetailed sales forecasts for the major antiretroviral classes, molecules and brands in each of the seven major marketsCase study analysis of the Canadian market including an in-depth assessment of the healthcare system and potential opportunities and threatsGilead is now the market leader in HIV with a portfolio of just four marketed products. Datamonitor expects JnJ/Tibotec and Merck to be the fastest growing companies over the next 10 years. While Tibotec only entered the field with the launch of its first product in 2006, Merck & Co.'s first-in-class Isentress reenergized its HIV efforts in 2007.
The HIV market is very concentrated, with the top 10 brands accounting for 80% of total antiretroviral sales across the 7MM in 2007. Truvada was the bestselling drug with revenues of $1.5 billion. Gilead and BMS' rapidly growing joint venture Atripla was already the fourth best selling HIV drug despite the absence of ex-US sales during the period.
While the 7MM and Canada are commercially the most significant for HIV, companies are now turning towards fast-growing emerging markets as new sources of revenue growth. The potential is there: the 7MM only account for 36% of the globally infected population, but more than 85% of revenues.Understand the changing market dynamics of HIV drugs, key success factors for leading brands as well as the impact of pending patent expiriesUnderstand the patient acquisition process with key inflection points in the decision-making process to choose antiretroviral drug brandsObtain full global, country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2007 to 2017 |
|
| Although Europe is leading the way, the biosimilar industry is very much in its infancy, with the perception of key decision makers critical to the initial rate of uptake. The opinion of key stakeholders, and the influence they wield, will therefore inform the strategy of both the branded and biosimilar contingents, in what is likely to become a battle to gain trust.An overview of the key drivers and resistors to biosimilar use.An outline of the key stakeholders in Europe and the US, and relative influence they have.An insight into the opinion of payers, physicians and hospital pharmacists, regarding biosimilar use.An understanding of how the industry will develop, and the strategies to be employed by the pro and anti biosimilar factions.Biologics use is set to grow, at a rate that far outstrips that of small molecule drugs. The considerably greater cost of biologics will therefore combine with increased utilization to put payers under pressure to promote biosimilar use.
Due to the complexity of biologic drugs, there are greater concerns regarding biosimilar safety and efficacy compared with standard generics, which are likely to only be alleviated following time on the market. Consequently, initial uptake will be greatly influenced by the perceptions of key stakeholders.
The opinion of physicians is considered important by both branded and biosimilar companies, and in Europe this group currently holds the most power. Although motivated to promote generics, payers and pharmacists to an extent, often defer to physicians in Europe, although there is evidence this is not the case in the US.Understand which drugs are subject to biosimilar erosion in Europe now, and going forward.Understand who the key stakeholders are and the influence they have on biosimilar uptake.Gain an insight into how the biosimilar industry will develop, and the strategies companies will employ to promote or resist uptake. |
|
| This brief provides a detailed study of the UK healthcare cash plan market, with information on market size and profitability, as well as developments in policy numbers. In addition, the size of the market is forecast out to 2012 under three scenarios reflecting different views on future conditions.Data on market size, policyholder numbers of the UK healthcare cash plan marketInformation on product penetration and consumer attitudes to cash plansForecasts of premium income until 2012 under three different scenarios, based on primary research and Datamonitor's own modelsNo company has been as active as the Simplyhealth group in consolidating the books of smaller players to achieve its present dominance in the healthcare cash plan market. The HSA Group, which later rebranded to become Simplyhealth, has consistently bought up smaller rivals in the market in order to expand cash plan numbers and regional coverage.Understand product penetration trends in the marketBenchmark your market share and premium income against your competitorsDevelop your future market strategy using Datamonitor's unique forecasts |
|
| Datamonitor expects the antihypertensives market to reach $37 billion, across the seven major markets, by 2017. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.Description of the competitive landscape in antihypertensives across seven major markets with market definition and overview.Definition of the unmet needs in the antihypertensives market.Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.Analysis of major events and brand dynamics affecting the hypertension market.The growth rate of the antihypertensive market is declining. The market is mature and does not present an attractive opportunity for R&D expenditure; consequently Big Pharma are shying away from the pursuit of novel mechanisms of action in favour of developing more efficacious combination therapies.
Cozaar's and Diovan's patent expiries in the US have the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets, are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market.
Novartis is set to strengthen its position in the antihypertensives arena; Tekturna is expected to achieve moderate sales and together with Exforge form a potential for market expansion. This however will be set back by the premature expiry of Pfizer's Norvasc patent.Quantify the future size of the antihypertensives market and identify opportunities for new products.Learn how recent changes related to product expiries will shape the antihypertensives market.Understand the barriers to uptake for novel antihypertensive agents, and the need for paradigm shift in clinical trial design. |
|
| Cytotoxic therapies are the second largest class of cancer therapeutics, generating branded drug sales of over $10 billion in the seven major pharmaceutical markets in 2007. Patent expiries for a number of agents that have achieved blockbuster sales over the years, means that the market continues to attract a considerable amount of generic competition.Analysis of the performance of each of the cytotoxic therapy cancer brands in the seven major markets, forecast to 2017Analysis and segmentation of the market at various levels including drug class, indication, company and sales growth rateAssessment of the leading cancer brands and drug classes to identify key success factors within this sectorQuantification of the market size of the cytotoxic therapy cancer brands in the seven major pharmaceutical markets with the rest of world marketsThe cytotoxic therapy cancer brands market is currently worth just over $10 billion and is forecast to grow to sales of almost $15 billion. The launch of the antimetabolite brands, Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitadine; Celgene) in the EU and Japanese markets contributes to this growth.
As a class, DNA-interactive cytotoxic therapy cancer brands contributed the highest proportion of sales in 2007 with $4.3 billion. This is in part, driven by the sales of Eloxatin (oxaliplatin; Sanofi-Aventis) and Camptosar. However, by 2017, the antimetabolite brands class are set to overtake.
Twenty four companies are involved in the development of currently approved cytotoxic therapy cancer brands, over half of which have more than one cytotoxic brand on the market. Sanofi-Aventis leads with four out of the 25 cytotoxic brands marketed, which made a collective $4,176m for the company in the seven major markets in 2007.Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2007 to 2017Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growthBenchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot |
|
| Targeted therapies are the top selling class of cancer drug, reaching sales of nearly $15 billion in the seven major pharmaceutical markets in 2007. The high growth of this therapy class makes it attractive to drug developers, resulting in 10 new entrants to the market since 2005. More drugs are likely to gain approval in the near future, contributing to a rapidly changing competitive landscape.Forecast sales of every marketed targeted therapy cancer brand in each of the seven major markets over the period 2007 to 2017Analysis and segmentation of the market at various levels including drug class, indication, company and mode of administrationComprehensive brand profiles and analysis, including approval dates, patent expiries and all key events likely to impact salesSnapshot of the targeted therapy cancer brands market in the rest of the worldThe targeted therapy cancer brands market is rapidly expanding and is forecast to maintain a high growth rate over the forecast period. The market will reach a value of over $42 billion by 2017 in the seven major pharmaceutical markets, growing at a CAGR of 11%
Approvals in new tumor types with high unmet need, use in earlier treatment settings and growing physician familiarity are among the factors likely to drive sales of the best performing targeted therapy brands. However, pharmacoeconomic pressures and the launch of generic and pipeline competitors will dampen the growth of certain brands
Monoclonal antibody targeted therapy cancer brands achieved higher sales than small molecule agents in 2007 and will remain the leading class over the forecast period. This is driven by the considerable success of the monoclonal antibody brands Avastin, Herceptin and RituxanQuantify the performance of each of the marketed targeted therapy cancer brands in the seven major markets over the period 2007 to 2017Assess the changing key opportunities and threats both for currently marketed and pipeline targeted therapy cancer brandsIdentify the leading brands in this market over the next 10 years and understand the key factors driving their success |
|
| As competitive pressures from the entry of generics post-patent expiry and new brands are growing, product lifecycles are evolving for the worst. Effective lifecycle management is becoming a must for Pharma looking to maximize their return on investment, regardless of which stage of the lifecycle a drugs is in. However such strategies are becoming most prominent immediately before patent expiry.Review of key reasons why lifecycle management is important nowAnalysis of key considerations Pharma need to take care of when devising lifecycle management strategiesDiscussion of most commonly used lifecycle management strategiesCase study analysis of successful and unsuccessful lifecycle management strategies employed by PharmaOne of the key challenges for Pharma is the loss of corporate memory regarding specific brands as brand managers spend on average only 18 months on one product with mainly short term goals in mind. Pharma need to take a structured approach to lifecycle management with a regular review of their strategies in response to internal and external events.
Lifecycle management should not be left until only few years are left to patent expiry. Revenues can be maximized during launch and peak phases by employing the right approaches. If a company starts planning its lifecycle management strategy early, it has more strategies available. However, many companies leave planning until late in the lifecycle.
Payers and physicians are becoming more sceptical of certain steps taken by Pharma as they consider them to be pure lifecycle management. Follow-on products such as reformulations and fixed dose combinations need to ensure they truly satisfy an unmet need in order to achieve even moderate uptake.Identify critical considerations for creating the optimal lifecycle management planUnderstand when the different lifecycle management strategies are most appropriateGain insight into recent successful and unsuccessful lifecycle management strategies |
|
| Alternative delivery methods under development have so far failed to live up to expectations. In many cases the technical difficulties associated with the delivery technique have not been overcome, leading to a return to injection based therapies. Big Pharma have all but exited the development of new insulin therapies leaving the field to small niche players.Comprehensive analysis of the current insulin antidiabetic pipeline detailing the broad range of developmental classes.A detailed clinical and commercial assessment of all key emerging therapies.Sales based sales forecasts for key late-stage developmental non-insulin antidiabetics agents in the seven major markets to 2017.Interest in inhaled insulin candidates has dropped significantly since 2007. Questions over reimbursement, social acceptability, pulmonary function and a potential lung cancer signal have led to the leading insulin companies cancelling their inhaled insulin programs
The insulin antidiabetic pipeline is mainly focused on new drug delivery methodologies rather than developing new injection based therapies. 76% of the pipeline is non-injection based therapies
Small companies dominate the pipeline with Big Pharma almost absent. Of the top twenty pharmaceutical companies only Abbott has an insulin candidateQuantify the future drugs in the insulin antidiabetic market.Identify licensing opportunities based on company portfolio and market needs.Assess the remaining market opportunity, where established therapies and other developmental compounds fail to address key unmet clinical needs. |
|
| As advances in omics technologies enable the development of high value molecular diagnostics, neurological conditions represent an attractive target for diagnostic companies. In this report, Datamonitor identifies the diseases in which early detection with a biomarker could significantly benefit the patient, gain payer approval, and ultimately expand the pharmaceutical market.Neurological conditions covered: Alzheimer's disease, Parkinson's disease, MS, epilepsy, migraine, insomnia, Huntington's disease and ALS.Overview of key biomarkers in development for each condition (including genetics).Identification of key factors required for the commercial success of neurological diagnostic biomarkers.Analysis of potential drug revenue gains due to improved diagnostics in Alzheimer's disease.A battery or algorithm of tests for each disease is likely to be available within the next 10 years. This is already the case for multiple sclerosis, the most mature neurological diagnostic market, with both clinical, imaging and in vitro diagnostics incorporated in a clear algorithm.
Revenue gained from earlier use (identification and incorporation of mild cognitively impaired patients) of potentially disease-modifying drugs in Alzheimer's disease could generate an additional $5 billion by 2017 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).
Neurology biomarker discovery and development is an attractive market for small biotechnology companies. The regulation of in vitro diagnostics is significantly less stringent than for pharmaceutical drugs. This decreases the considerable financial barriers to entry usually faced by biotechnology companies orientated towards drug discovery.Assess which diseases have the highest unmet need for new biomarkers.Appreciate the lucrative potential of earlier treatment of neurodegenerative conditions.Forecast the impact of improved diagnostics on neurological drug sales. |
|
| At the forefront of novel technologies; momentum is steadily building for the development of stem cell products to address cardiovascular disease. The most active areas are those with high clinical unmet need heart failure, cardiomyopathy and ishemic heart disease.Analysis of the current unmet needs in cardiovascular disease marketsOpinion leader commentary on key clinical trials and market landscapeReview of the clinical and commercial status of stem cell therapy for cardiovascular diseaseReview of the clinical and commercial status of gene therapy for cardiovascular diseaseDatamonitor's analysis demonstrates how the most innovative drugs offer the greatest growth potential for their respective markets. In the mature cardiovascular market, commercial success must be derived from innovative approaches with unique clinical benefits.
The array of innovative gene and cell products emerging from young companies exposes investment opportunities for venture capitalists, Big Pharma, as well as partnering opportunities for technology companies that can offer compatible catheters, or cell delivery devices.
There awaits an outstanding commercial opportunity for innovators who address clinical unmet need in this market, as a number of companies will see their key revenue generators melt away as they lose patent protection.Understand the need for innovation in the cardiovascular market.Up to date insight into the commercial and clinical status of cardiovascular gene and cell therapiesUnderstand the barriers to commercialization of novel therapies, with expert commentary |
|
| Vaccines have re-emerged as successful revenue generators for Big Pharma, with adults and the elderly now increasingly coming into focus as the next big opportunity in this sector. An aging population, rising disease awareness and new technologies to overcome the scientific hurdles linked to the weakened immune response in the elderly are all contributing factors.Assessment of pneumococcal and zoster disease incidence, in-depth analysis of existing vaccines and key pipeline compoundsReview of current and expected future immunization guidelines as well as existing and forecast immunization rates10-year sales forecast on a population basis for Zostavax, Prevnar 13 and Pneumovax-23Overview of current booster vaccine recommendations and commercial landscape with analysis of future market driversFollowing the great success of Wyeth's heptavalent pneumococcal vaccine Prevnar in the infant sector, Datamonitor believes that Prevnar 13 could achieve blockbuster status in adults and elderly alone, if a superior efficacy compared to Pneumovax 23 is confirmed in ongoing clinical trials.
Merck & Co's Zostavax is the only available vaccine for the prevention of shingles and will continue to enjoy a monopoly in this promising market due to a lack of pipeline competitors. Datamonitor predicts peak sales between $1.5 and $2 billion.
Sanofi Pasteur and GSK are the leading players in the booster vaccines market. Overall, Datamonitor predicts significant growth potential in this sector, based on both geographic expansion of existing booster indications as well as the potential introduction of additional booster vaccinations for new indications.Size the available market opportunities and identify the unmet medical needs when immunizing an elderly patient populationGain insight into key opinion leaders' thinking on vaccines for the elderlyUnderstand and identify the key challenges to achieving a better penetration of the next big opportunity in the vaccine area |
|
| With a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies. Estimated to total around $650m in 2007 in the seven major markets, Datamonitor forecasts the market to grow to over $2.4 billion in 2017.Analysis of clinical trial design and treatment guidelines in fibromyalgia.Fibromyalgia market sizing assessment with detailed methodology.Detailed profiles of key late-stage pipeline products for fibromyalgia, with indication-specific forecasts to 2017.Case study analysis of Pfizer's launch strategy for Lyrica (pregabalin) as well as assessment of development timeline.The approval of Pfizer's Lyrica transformed the previously unchartered fibromyalgia market and provided a new level of validity for this disputed condition.
In June 2008, Eli Lilly's dual serotonin and norepinephrine reuptake inhibitor (SNRI) Cymbalta (duloxetine) became the second FDA approved fibromyalgia treatment. Datamonitor forecasts seven major market Cymbalta sales for fibromyalgia to peak at in excess of half a billion US dollars in 2012 prior to US and EU patent expiries.
As has been successful for Pfizer, televised direct-to-consumer (DTC) drug advertising campaigns will continue to be an important marketing tool for new players, providing a boost to sales and adding further legitimacy to the condition.Understand the current fibromyalgia market dynamics and how they are expected to evolve out to 2017.Benchmark key late-stage pipeline fibromyalgia compounds against the current market leading brand, supported by insight from key opinion leaders.Assess seven major market sales forecasts of marketed and key late-stage pipeline fibromyalgia drugs. |
|
| Asthma is managed using a step-wise approach, with bronchodilators to relieve symptoms of airflow limitation and controller medications to target underlying inflammation. Datamonitor's research shows that almost all patients (even those with mild intermittent asthma) receive some type of controller medication as their baseline treatment, which is in line with international management guidelines.Patient segmentation with regards to disease severity, asthma phenotypes, co-morbidities and exacerbationsTreatment choice split by line of therapy and disease severityPerformance of asthma therapies in terms of factors such as efficacy, onset and duration of action, side effect profile, delivery method and costPhysician awareness and perception of drugs in developmentRecently, the classification of asthma has shifted to the concept of disease control in order to acknowledge the variability of the disease. Datamonitor research showed that around half of the physicians have taken on this new asthma classification, which may illustrate the transition away from the traditional severity classification.
The ICS class as a whole scored rather low on speed of onset, which may indicate an unmet need in this class. The traditional products Flixotide/Flovent (fluticasone) and Pulmicort (budesonide) scored consistently higher than the novel products Asmanex (mometasone) and Alvesco (ciclesonide).
Of the combination products in development, physicians were most aware of GSK's Beyond Advair, probably due to the fact that GSK already has had Advair/Seretide on the market. The other four ICS/LABA combinations were less well-known since they all come from companies without a current combination product on the market.Target physicians more effectively through an understanding of prescribing behavior and its influences.Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products.Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies. |
|
| As healthcare organizations increasingly turn to IT to decrease costs, improve the quality of care and increase access to care, it is important for technology vendors to understand where growth opportunities exist in the global healthcare market.Understand the opportunity size for technology spending in the global healthcare marketIdentify potential areas for spending growth amongst healthcare organizationsSegment the healthcare market by spending opportunities |
|
| With the growing cost of developing novel drugs, combined with the fact that fewer such drugs are gaining regulatory approval, the use of lifecycle management is playing an ever-more important role in the increasingly cost-conscious pharma industry. Rx-to-OTC switching is one such strategy employed to either enhance existing franchise revenues or protect branded revenues from generic competition.Overview of the Rx-to-OTC strategy, analyzing why, when, where, what and how to implement such a switch strategyIdentification of drivers and resistors of Rx-to-OTC switching across the seven major pharmaceutical marketsCase study analysis of the most recent Rx-to-OTC switchesFor Rx-to-OTC switches to succeed, there needs to sufficient differentiation between the existing Rx drug and the new OTC product. However, differentiation must meet a genuine unmet need. Differentiation for the sake of it is unlikely to produce a winning Rx-to-OTC switch strategy.
The volume of the OTC market is declining in the majority of the seven major markets. If this trend continues, it will not only impact the profits of OTC manufacturers, but also national cost-containment measures to reduce ever-escalating healthcare costs.
At present, Rx-to-OTC switches in the five major EU markets are decided at a national level. However, despite ongoing discussions, there are numerous barriers to harmonized EU Rx-to-OTC switches. Consequently, it is unlikely that in the EU harmonization will happen at least in the foreseeable future.Identify the recent trends in the Rx-to-OTC market, including which are the most popular OTC indications, and who is implementing Rx-to-OTC switchesGain insight into the drivers and resistors of implementing Rx-to-OTC switches across the seven major marketsRecommendations on how to maximize the commercial success of an Rx-to-OTC switch |
|
| The treatment of menopausal symptoms is a common clinical challenge, with vasomotor symptoms affecting an estimated 75% of women aged over 50 years. Hormone replacement therapy (HRT) has formed the mainstay of treatment for almost 60 years and is highly efficacious. However, concerns surrounding the safety of HRT have led to an increase in demand for non-hormonal alternatives.Overview of menopause, including a review of the prevalence of vasomotor symptoms to better understand the size of the target patient population.Summary of topical issues in the treatment of menopausal symptoms and rationale for a non-hormonal approach treatment.Review of pipeline non-hormonal drugs and analysis of their future potential in relation to currently available hormone replacement therapy.Insight from interviews with seven key international experts in the field of menopause and associated treatmentsThe key opportunity for non-hormonal treatments lies in capturing sales that have been lost by the hormonal treatments since the WHI results. Despite increased demand, the current R&D pipeline for non-hormonals is small and lacks innovation. Wyeth's Pristiq could be first to market although regulatory delays indicate possible non-approval.
Returning confidence in HRT among gynecologists and the recent upturn in sales of these therapies represents a growing barrier to entry for non-hormonal drug companies. Nevertheless, prevailing mistrust of HRT among primary care physicians (PCPs) and eligible patients represents a key market opportunity for non-hormonals.
In view of the lower efficacy of non-hormonals compared to HRT, it is expected that uptake will be strongest among patient groups for whom HRT is contraindicated, as well as highly symptomatic patients who do not wish to receive HRT due to safety concerns. Mildly symptomatic patients also represent a key target group.Understand key opinion leaders views on topical issues in the current and future treatment of menopausal symptoms.Explore the R&D pipeline for non-hormonals and the future directions of the market as identified by interviewed KOLs.Identify the drivers and resistors for key non-hormonal drug treatments in the market. |
|
| The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017. The growth in the market is spurred on by the uptake of Pfizer's Lyrica (pregabalin), forecast to reach almost $3 billion in sales by 2017. Vimpat is the most promising pipeline drug, forecast to take some $480m by 2017.Analysis of patient potential, unmet needs and clinical trial design in the neuropathic pain market.Overview of key marketed brands, late- and early-stage pipeline drugs.Country-specific sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs.Identification of future market events that are expected to affect neuropathic pain revenues.UCB's Vimpat (lacosamide) demonstrates the most potential in the pipeline and is well suited to compete in this market. Datamonitor has forecast Vimpat to generate over $480m, over a third of the total pipeline sales by 2017.
Neuropathic pain offers diverse market opportunities, with niche underserved neuropathic pain indications (e.g. HIV associated neuropathic pain) offering a good market entry point.
Following the recent negative FDA advice on Cephalon's Fentora, Datamonitor has forecast that the drug will not launch for neuropathic pain. This is a blow to the development of a niche breakthrough neuropathic pain market.Benchmark key late-stage pipeline neuropathic pain drugs against current market leading brands.Assess country-specific (US, Japan, France, Germany, Italy, Spain and the UK) sales forecasts of key late-stage pipeline drugs and marketed brands.Understand unmet needs and opportunities in the neuropathic pain market based on key opinion leader comments. |
|
| Governments and payers across the seven major markets are implementing cost-cutting initiatives to combat escalating healthcare costs, putting even greater pressure on pharma companies. In addition to the credit crunch, ever fewer novel products are coming to market, contributing to the declining return on investment.Overview of P&R issues in the market today and their impact on branded PharmaIntroduction to the current P&R tools utilized across the seven major markets to contain costsAnalysis of each of the seven major markets, examining both the healthcare systems and the key P&R infrastructureIdentification of trends and recommendations shaping national P&R environmentsIt is now a perquisite to perform pharmacoeconomic assessments early on in the drug development process and provide cost effective evaluations to ensure access to reimbursement lists
In the, US pharma companies can expect the Federal government and insurance providers to seek out negotiations to cut drug costs. Presently, Medicare is unable to negotiate drug prices with Pharma, although a Democratic government will want to amend legislation giving it more power to challenge Pharma on drug prices
Parallel trade will continue to play a role in driving down drug prices in Europe. However, as drug price differences between EU countries decreases due to reference pricing, coupled with the claw-back system imposed on pharmacies, the incentive to use parallel traded products will progressively weakenGain a clear understanding of the recent changes in the P&R environment across the seven major markets and how this is impacting pharma companiesReview recent P&R trends in the seven major markets based on Datamonitor analysis and primary research conducted with key stakeholders in the industryProvides analysis of today's market situation, focusing on the up coming US presidential elections and the potential impact on future P&R initiatives |
|
| With the rising costs, length and complexity of clinical trials, drug development is subject to huge delays, translating into delays in getting a drug to market and millions of dollars in lost sales. Optimizing the recruitment process through web-based technologies can cut delays in clinical trials and can also be used to maintain relationships with patients to improve the clinical trial process.Overview of the benefits and drawbacks of online recruitmentAnalysis of the online patient recruitment processAnalysis of the key players in patient recruitmentOverview of patient recruitment via physiciansWith rising internet penetration, online recruitment offers increased geographical reach and can provide huge cost savings as there is no costs for staffing or expensive advertising. A significant advantage of the internet over the other more traditional media, is that it offers an educational platform as more information can be given to patients.
Although about half a billion dollars are spent annually on mass media patient recruitment advertising and promotion, only a minority of the public has a basic understanding of the clinical research process. Poor perception was seen as the biggest hurdle in patient recruitment.
Once the potential volunteers have been targeted, it is important to convert them into participants. The key to successfully attracting and recruiting patients, is to work closely with patients and investigators, with efficient feedback mechanisms and a cohesive strategic plan in order to achieve a "patient-centric" approach for enrolment.Explore how patient recruitment for clinical trials can be maximized through web-based toolsUnderstand the process of online patient recruitmentGain insight into how patient relationship management affects patient recruitment and the clinical trial process |
|
| Stroke is one of the top three causes of death and its incidence in the seven major markets is expected to increase in the next ten years because of an aging population. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awareness of stroke is poor.Analysis of patient potential, unmet needs and clinical trial design in acute stroke;Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline;Detailed profiles of key compounds in development for use in acute stroke, with forecasts of drug revenues to 2017;Review of the recent failures in acute stroke (NXY-059 and NovoSeven)In the setting of acute stroke, a patient's treatment options and recovery prospects are a function of time. Therefore any delay related to the time-to-treatment constitutes a resistor to market entry and uptake for stroke therapies in the acute care hospital setting.
The R&D landscape is shaped by the need to minimize the commercial risk associated with developing drugs for the acute-care stroke market - the majority of the companies contribute only one candidate drug to the acute stroke pipeline.
The future prognosis for the acute stroke therapy is marred by the long list of failures, especially of neuroprotectants. Thrombolytics are also plagued by shortcomings in trial design, which result either in discontinuation of the drugs, or prolonged development that leads in its turn to the low credibility of the compounds.Understand clinical and environmental unmet needs in the acute stroke market based on key opinion leader commentsBenchmark key late-stage pipeline products against the current market leader and class comparator;Assess the 7 major markets (US, Japan, 5 major EU) sales forecasts of late-stage pipeline drugs and examine their clinical and commercial potential. |
|
| With several recent non-approvable decisions in the osteoarthritis market since 2006, Datamonitor has updated its forecast to account for the effect on the market. We have revised the market outlook over the next 10 years using the latest IMS data. We expect the market to grow steadily, with a CAGR from 2007 to 2017 of 3.2%, to reach sales of nearly $5.5 billion in 2017.This report gives a strategic analysis of the likely impact that recent events will have on the osteoarthritis marketIncludes osteoarthritis-specific and total brand sales forecasts for the key brands in the seven major markets to 2017This report provides a global market snapshot by including osteoarthritis-specific sales analysis for leading brands outside the seven major marketsThis report includes updated forecasts of nearly 130 currently marketed products and reassesses pipeline product launch dates and sales forecastsAfter three years of decline, market sales grew by 0.8% (2006-07) to reach $4 billion in the 7MM in 2007. Driving growth was an increase in sales of COX-2, non-narcotic analgesic and corticosteroid classes. Market sales will reach $5.5 billion by 2017 (3.2% CAGR) boosted by pipeline product launches, particularly NicOx's naproxcinod.
Lessened side effect concern and clever marketing contributed to the rebound in Celebrex sales. Also contributing to Celebrex's reprise was the Japanese launch in June 2007. Celebrex will remain the market leading brand for osteoarthritis treatment until patent expiry in 2014, when more than 70% first year generic erosion is forecast.
Arcoxia (etoricoxib) and Prexige (lumiracoxib) will not launch in the US as previously predicted. The COX-2 pipeline has collapsed with little sign of future promise. This counters the rise in Celebrex and Arcoxia sales, which show that opportunities exist, but at present regulatory requirement generates a large barrier to entry.Quantify the current size of the seven major markets and the trends in the rest of the worldUnderstand when late-stage pipeline products will launch and what impact this will have on the market during the forecast period 2007 to 2017Assess the impact of events, such as patent expiries, on the osteoarthritis-specific sales of key brand name products |
|
| As healthcare organizations implement electronic health records, they are becoming increasingly aware of the ways clinical decision support tools will help them improve quality of care, comply with clinical standards and take part in pay for performance initiatives. However, CDS includes a vast range of solutions, many of which are difficult to implement.Identifies the key factors driving adoption of CDSPinpoints common pitfalls in CDS implementationProvides a framework for future CDS solutionsThe culture of medicine is resistant to CDS
CDS tools of the future will be patient-centric and focus on diagnosis
Clinical intelligence will change the way medicine is practicedUnderstand where CDS is today and where it will be in 5 yearsAlign product messaging with what will resonate best with healthcare organizationsIdentify strategies that will increase CDS adoption |
|
| Drug repositioning has several advantages over traditional discovery-reduced cost, risk and time to market-compared with traditional discovery, providing an attractive prospect for Big Pharma, scrambling to fill pipelines in an increasingly harsh market environment. As competition to inlicense candidates drives the price of this strategy up, repositioning presents a cost effective alternative.An outline of what drug repositioning is, and what is driving it.An overview of the key players in the repositioning industry their methodologies and specialities.Case-studies describing a number of drugs which are or have been repositioned.An insight into how repositioning will change going forward.Despite increasing R&D investment, productivity has been declining, at a time when Big Pharma is contending with late–stage pipeline failures and more rigorous drug approval procedures, in addition to external challenges in the form of generic competition and pricing pressures.
The cost savings, accelerated path to market, and lower risks that repositioning brings relative to traditional discovery are attractive to Big Pharma, which has thus far been filling pipeline gaps by in–licensing, a practice which has become more expensive as competition for candidates increases.
The companies involved in repositioning currently differ greatly in the methodologies used, in addition to their disease focus, however as the strategy gains traction, the industry is likely to undergo considerable consolidation. Understand what drug repositioning is, and why it is important. Become aware of who the key players in drug repositioning are and how they operate.Gain an insight into how drugs have been, and are being repositioned. |
|
| While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: “in-stent thrombosis”. Opinion leaders are divided over the gravity of this problem, but positive safety data are required to restore physician confidence in drug eluting stents.Review of the acute coronary syndromes (ACS) – the indication that drives the PCI market.Opinion leader commentary on guideline developments and key clinical trials.Review of the key drug classes used in conjunction with PCI and the current opinion on facilitated PCI.Opinion leader discussion of currently marketed stents, key clinical trials in stents, and the evolution from bare metal to drug eluting stents.Since the introduction of PCI the procedure rate has increased dramatically making it one of the most common interventional procedures for heart disease. Use of PCI differs across the major markets, with this more aggressive revascularization strategy receiving greatest uptake in the United States, where coronary artery disease is most prevalent.
Evidence that facilitated PCI improves clinical outcomes remains inconclusive, although opinion leaders consider the premature interruption of ASSENT-4 to advise against facilitation with thrombolytics; the ACC/AHA guidelines suggest facilitation only in “high risk” patients, whereas the ESC say they find no evidence to recommend it at all.
While drug eluting stents have been successful in reducing restenosis rates from 20-30% to single digits, there have been safety scares over a new problem: “in-stent thrombosis”. Cordis’s Cypher and Boston Scientific’s Taxus have received some unfavourable press, but physicians are still enthusiastic about Abbott’s new stent, Xience.Understand the PCI market, the driving indications and the drug classes prescribed in PCI patients.Gain physician opinion on current treatment practice and how it might evolve.Understand the negative publicity which has caused the robust drug eluting stent market to falter. |
|
| Advanced heart failure is a growing issue. Existing pharmacological strategies increase the survival rates of acute heart failure patients, providing a growing source of patients with advanced disease. In view of long waiting lists for heart transplantation and the growing lack of donors, cardiac resynchronization and mechanical circulatory support devices have demonstrated promising results.What are the current definitions, diagnostic methods and treatment approaches of the early stages of the disease?What are the main issues surrounding treatment approaches in the advanced stages of the disease?What is the current role of cardiac resynchronization therapy in treatment of advanced heart failure?What are the main non-pharmacological options as alternatives to heart transplantation in advanced heart failure?With no new drug therapies addressing advanced heart failure and existing pharmacological strategies failing to compensate a weakening heart, alternative, non-pharmacological solutions have to be found. In view of long waiting lists for heart transplantation and the growing shortage of donor hearts, the focus of treatment must shift onto devices.
Ventricular dyssynchrony is a well recognized problem in advanced stages of heart failure. Clinical trials investigating ventricular dyssynchrony cardiac resynchronization have demonstrated promising results. However, this technology provides only temporary, symptomatic relief and neither cures nor fully stops the progression of the disease.
In light of the growing shortage of donor hearts and failing pharmacological strategies, an artificial mechanical heart has been a long sought-after technology. Although the developments started decades ago, a fully implantable total artificial heart is still at the concept stage, with many years of research and development yet to come. Understand current definitions, diagnostic methods and treatment approaches in advanced heart failure Current dynamics and future trends of the technology developments treating advanced heart failureMajor technological and industry issues surrounding technological progress and new product development |
|
| As the reimbursement status for the cost of hospital-acquired infections is under pressure by payors, interest in preventing these complications at the outset is growing. Nosocomial vaccines offer one route of prevention. This report assesses the clinical pipeline candidates five key nosocomial pathogens and their potential market environment including target population size estimates.In-depth analysis of epidemiology, spread, costs and reimbursement linked to nosocomial infections across the major Western marketsThorough general and pathogen-specific assessment of the market potential for the major 5 classes of nosocomial vaccinesIn-depth discussion and sizing estimates of potential target groups for nosocomial vaccines by pathogenReview of alternative strategies for infection prevention and comparison with vaccinationThe increasing incidence and severity of nosocomial infections has sparked an interest in preventive strategies such as vaccination. High costs and reimbursement cuts associated with nosocomial infections provide a strong incentive for healthcare stakeholders to invest in infection prevention, providing a strong rationale for vaccine development.
In the highly cost-conscious nosocomials market, a prudent definition of vaccination target groups will be crucial to satisfy the stringent cost-benefit analysis. Whereas patients undergoing planned hospital stays will benefit from vaccination, alternative prevention methods may be preferable for immuno-compromised, newborn and acute patients.
Datamonitor believes that C. difficile vaccines will have the easiest route to market due to the large and well-defined target population and a high unmet need. Vaccines against S. aureus and P. aeruginosa could prove valuable in selected target groups, whereas there is only a limited potential for vaccines against S. epidermidis and enterococcus.Review the epidemiological, clinical and economical factors driving new product decisions in nosocomial vaccine development.Gain insight into the pipeline through a discussion of key candidates in clinical development for five nosocomial pathogens.Understand and identify key market opportunities by reviewing sizing estimates for key target populations by pathogen. |
|
| In 2007, the market value of HRT for menopausal symptoms saw its first upturn since the Women’s Health initiative (WHI) study results in 2002; highly publicized findings which linked HRT to cancer and cardiovascular safety risks. The recent growth of the market is due in part to the increasing price of HRT products but can only be sustained by a similar increase in volume sales.Analysis of patient potential, unmet needs, market dynamics, and clinical trial design in HRT, supported by opinion leader comment.Assessment of pipeline drugs and future treatment trends and their impact on prescribing patterns and behavior. Sales based market forecasts to 2017, providing a breakdown by dose-strength, marketed brands and pipeline drugs, drug class and region. A review of the opportunities and threats facing HRT manufacturers in the seven major markets.The market growth seen from 2006 to 2007 will be maintained by a growing number of women requesting pharmaceutical treatment for their menopausal symptoms in the next decade. The value of the seven major markets combined is expected to grow by over $1 billion as volume sales increase by 0.5% and innovative products set higher price points.
New mechanisms of action that prevent the agents from affecting breast and uterine tissue should diminish safety concerns and revolutionize the HRT market. Two late-stage pipeline products, Wyeth’s Aprela (bazedoxifene, conjugated equine estrogen) and Bionovo’s MF-101 (liquiritigenin) are expected to generate combined revenue of $893m in 2017.
Reactive strategies, such as the launch of alternatively delivered therapies and low dose reformulations, were useful, short-term revenue generators in the wake of the WHI publication. Now the market profile must be raised, and physician/patient education used to maintain growth in the long term.Quantify the future size of the HRT market and the number of women currently eligible for treatment for menopausal symptoms in the US, 5EU, and Japan.Understand unmet needs, and opportunities/threats in the HRT market based on key opinion leader comments.Benchmark key late-stage HRT compounds against current market leading brands. |
|
| Non-small cell lung cancer accounts for about 80% of all lung cancers. In 2008, the incidence of NSCLC is forecast to exceed 367,000 new cases in the seven major pharmaceutical markets. The high incidence of the disease and the large unmet need make NSCLC an attractive market for new drug development.Research and analysis of the NSCLC pipeline with in-depth clinical and commercial assessment of Phase III candidatesSeven major pharmaceutical market sales forecasts to 2017 for key pipeline candidates incorporating product specific assumptions and eventsSegmentation and analysis of the current NSCLC pipeline by developmental phase, drug class and developerAnalysis of the NSCLC market potential, including identification of unmet needs, commercial opportunities, and key trends in developmentDatamonitor has identified 104 drugs in the NSCLC pipeline, 15% of which are in late-phase development. Collectively, these late-phase products have a forecast sales potential of up to $4,056m by 2017 in the seven major pharmaceutical markets.
Molecular targeted therapies are the focus of R&D in NSCLC, accounting for 60% of the entire pipeline. Of the molecular targeted therapies in late-phase development, Erbitux (cetuximab; ImClone/Merck Serono/Bristol-Myers Squibb) is forecast to achieve the highest level of sales, with $473m by 2017.
The current late-phase pipeline is unlikely to satisfy the high level of unmet need in the treatment of NSCLC. However, pipeline drugs are still likely to realize notable uptake, despite offering only incremental improvements in efficacy or toxicity.Acquire a detailed appreciation and impartial perspective of the NSCLC pipelineIdentify the key products in late-phase development based on sales forecasts to 2017 and Datamonitor’s drug assessment methodologyIdentify opportunities and risks influencing R&D in NSCLC, unmet needs in the treatment of the disease, and trends in current development |
|
| The ADHD market is currently valued at $3.85 billion and is set to increase over the next 10 years at a CAGR of 1.2%. Despite the continuing dominance of stimulant drugs, the 2002 launch of Strattera, the first non-stimulant treatment for ADHD, and the 2006 launch of Daytrana have served to open up the market, giving patients and physicians a greater choice of treatment options.Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs.Analysis of patient potential, unmet needs and clinical trial design in the ADHD market.Overview of key marketed brands and late stage pipeline drugs.Identification of future market events that are expected to affect ADHD revenues.Estimated to be twice the size of the pediatric ADHD population, the highly prevalent, yet largely untapped, adult ADHD population continues to represent an attractive niche to target. The rising awareness of ADHD brought about by marketing campaigns for Adderall XR and Strattera has paved the way for the entry of additional adult ADHD drugs.
Due to a lack of innovation, none of the forecast drugs have the potential to match the commercial success experienced by currently marketed brands. Shire's Intuniv (guanfacine) is expected to be positioned as a second-line treatment and will benefit from the company's established reputation in the market.
J&J's Concerta's strong uptake is due to its first-to-market status as a once-daily ADHD treatment. Anticipated approval for use in adult patients, combined with Adderall XR's patent expiry will see Concerta becoming the market leader by 2017. However, owing to patent litigations, the timing of Concerta's genericization remains uncertain.Benchmark key late-stage pipeline ADHD drugs against current market leading brands.Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.Understand unmet needs and opportunities in the ADHD market based on key opinion leader comments. |
|
| An overview ofthe market for portable inhalers, looking at market shares,usefulness as tools for franchise protection and -expansion. Patient- and physician preferences are being analyzed as well as suitablility of molecules and inhaler types.,Summary of the advantages and disadvantages of the main types of portable inhaler devicesMarket overview highlighting CFC-free and CFC-containing devices and devices delivering branded and generic molecules, based on 2007 IMS Sales DataOverview of portable inhaler devices in non-pulmonary diseases, including inhaled insulin for the treatment of diabetesAssessment of opportunities to use portable inhaler devices as key factors in a product's commercial success throughout its lifecycleAlthough a direct link between the type of device and level of disease control has never been proven, the latter is possibly indirectly influenced by the respective device's ease of use, its airflow resistance and the patient's device preferences.
There are still opportunities in the asthma/COPD market to gain market share by differentiating with an improved inhaler device. One of such strategies would be to introduce a product line of different molecules in the same device model in order to give physicians the opportunity to minimize the scope for error on the patient side.
Inhaled drugs are increasingly being developed for systemic use in non-pulmonary diseases. Reasons for this include improved patient acceptance and compliance and a faster onset of action. However, the commercial failure of Pfizer's inhaled insulin illustrates the difficulties in striking the right balance.Understand key advantages and disadvantages of different types of portable inhaler devicesIdentify future challenges for portable inhaler devices and best method of meeting theseAssess the respiratory market's segmentation and dynamics by device type and brand/generic split |
|
| This model sizes the market for claims processing in healthcare payers from 2007-2013. The model is segmented into government and private payers. In addition the market is broken down between BPO and in-house services.See market sizing for USA, UK, Canada, France, Germany and Australia from 2007-2013 for claims processing in healthcare payers.Gain insight into where the opportunities and what the growth will be from 2007-2013. |
|
| In challenging market conditions that healthcare payers are faced with this report analyzes the claims processing market for healthcare payers. The report looks at how claims processing can bring an increased return on investment (ROI) to payers and what strategy should be taken in order to achieve successful adoption.The evolution of healthcare is creating a challenging environment for healthcare insurersConsolidation within the industry creates tough technological decisions for insurersThe varied structure of healthcare across the markets creates a challenging environmentVendors with flexible offerings to healthcare payers will achieve the most successThis report looks at the drivers and inhibitors behind claims processing for healthcare payers. It analyzes the strategy healthcare payers need to adopt in order to maximize their success.Understanding the challenges facing healthcare payers and how these effect their purchases on claims processing.View market sizing for US, UK, Germany, France and Australia from 2007-2013 |
|
| The Critical Care Community is currently at its most organized, and motivated, and on a mission to improve outcomes in sepsis. This is driving a rigorous assessment of care strategies which is gathering speed and showing results. This will yield many opportunities for developing products, but current interventions' roles will change, with impacts on how they are measured, used and valued.Insight into clinical and commercial developments tackling predisposition, infection, response and organ dysfunctionA translation of the complex, multifaceted processes involved in sepsis into commercial realities for industryPerspectives from Contract Research, Biotech, Pharmaceutical and Diagnostics sectors and leading figures from the sepsis and critical care communityAssessment of the impact of the Surviving Sepsis Campaign and the changes in its latest set of guidelines on prescribing physiciansThe critical care community's rigorous assessment of current management strategies is now gathering speed and showing results, gaining more converts and highlighting new perspectives on sepsis-related processes
Current interventions used in sepsis are typically either repurposed from other disease areas, or based on nascent understandings of the processes in play
Whilst this improved understanding may yield many new opportunities for developing new interventions, the understanding of the roles of current interventions may be turned upside-down, with implications for how they are measured, used, and indeed, valued in improving outcomesUnderstand the clinical and commercial characteristics and priorities for an increasingly complex therapy areaIdentify the elements of strategies that will either kept players at the top of their field or fail completelyUnderstand how these businesses and strategies relate to your interest in the market, and how to position your products and services accordingly |
|
| The opioid market is currently valued at $7.7 billion and is set to increase over the next 10 years at a CAGR of 2.4%. Despite this market being exclusively comprised of old genericized molecules, novel formulations and delivery methods have stimulated growth over the last 5 years. This growth is set to continue as current market players instigate lifecycle management strategies to retain value.Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs.Analysis of patient potential, unmet needs and clinical trial design in the opioid market.Overview of key marketed brands, late- and early-stage pipeline drugs.Identification of future market events that are expected to affect opioid revenues.Short-acting opioids represent good in-licensing opportunities for companies with large sales and marketing resources. This market is expected to triple in value over the next 10 years, driven by Cephalon's Fentora for use in breakthrough pain, and supported by other new short-acting fentanyl formulations.
The long-acting opioid market was valued at over $3 billion in 2007, and is due to grow until the patent expiry of market leader OxyContin in 2011. After a short lived decline, market growth will be stimulated by the launch of anti-abuse formulations, a technical development anticipated to create a $1 billion market.
The topical market represents an opportunity for companies to enter a comparatively underserved market. Although Johnson and Johnson's market leading Duragesic (fentanyl patch) has faced generic opposition since 2005, sales remain relatively strong due to brand strength and the lack of branded competition.Benchmark key late-stage pipeline opioids against current market leading brands.Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.Understand unmet needs and opportunities in the opioid market based on key opinion leader comments. |
|
| With the AD market entering a pivotal phase, Datamonitor has conducted several scenario forecasts in order to explore the possible market outlook over the next 10 years. Several pioneering Phase III disease slowing therapies offer blockbuster potential. However, should these drugs fail Phase III trials, generic competition of current therapies will see the market value decline.Overview of key marketed brands and late-stage pipeline drugs.Indication-specific sales volume and value forecasts to 2017 under four different scenarios.Identification of future market events that are expected to affect AD drug revenues.Analysis of patient potential, unmet needs and clinical trial design in AD.Datamonitor's base scenario reveals three blockbuster potentially disease slowing drugs in the current late-stage pipeline. Wyeth/Elan's bapineuzumab has potential to generate multi-billion dollar revenues, and become one of the most lucrative drugs in medicine.
The entry of potentially disease slowing therapies will not have a significant negative impact on the sales of branded current treatments. Along with the likely use of combined disease slowing and symptomatic treatments, slowing disease progression might actually increase the therapeutic window for symptomatic drugs.
Scenario forecasts reveal a future upper limit market value of $12.7 billion to a lower limit value of $1.9 billion across the seven major markets in 2017. The affect on forecast sales revenues of different US AD prevalence rates and the success or failure of clinical programs on each key pipeline drug is explored.Appreciate the lucrative potential of disease slowing AD therapies, and the impact of this class on the currently marketed symptomatic drugs.Assess region- (US, Japan and 5EU) and scenario-specific sales forecasts of key late-stage pipeline drugs and marketed brands.Understand unmet needs and opportunities in the AD market based on key opinion leader comments. |
|
| Antibody-based agents represent a novel approach to the treatment and prophylaxis of infectious diseases. In recent years, considerable interest has been expressed in their further development, driven by advances in technology that improve manufacturing cost and tolerability: fully human antibody reagents avoid the toxicities associated with traditional human- or animal-derived serum therapy.An overview of the past, current and emerging technologies for biologics as well as obstacles faced in development.Discussion of antibody products in development for several viral infections and their probable use.An assessment of pipeline antibody agents targeting important bacterial and fungal nosocomial pathogens.A review of the key unmet needs within bacterial, viral and fungal infections along with an outline of the commercial outlook for antibody agents.Antibodies offer several advantages over conventional anti-infectives and vaccines but their cost and mode of administration limits their use in certain areas. A high unmet need and defined target groups are required to gain commercial success. Pipeline products fulfilling these criteria have a greater chance of commercial and scientific success.
Accounting for the majority of nosocomial infections, MRSA is the most popular target for antibody development. Despite concerns over resistance there are still several antibiotics that can treat multi-drug resistant S.aureus, reducing the need for antibody-based therapeutics. The greater need lies in treatment of Pseudomonas and fungal infections.
For most viral infections, conventional therapies are able to control disease progression effectively. In HIV and HCV the real need is for a cure or preventative measure but the majority of pipeline products are being developed for treatment of these infections.Identify the key antibody products in development for bacterial, viral and fungal infections.Examine the remaining and emerging unmet needs in the infectious diseases market and identify opportunities for antibody product development.Gain an overview of the commercial outlook for antibody based products and their likely positioning in the prophylaxis and treatment of infections. |
|
| Ideally drug supply should be a simple and transparent chain that connects the manufacturer and patient in as few steps as possible, however in practice it can be a highly circuitous one that includes several intermediaries before reaching a pharmacy. This increases the risk of counterfeit drugs and facilitates parallel trade, both leading to lost sales for the manufacturer.An overview of the drug supply chain in Europe and the US.Identification of the key players in the drug supply chain.Coverage of recent trends and key events in the distribution industry.Analysis of the impact of new events on the key stakeholders.With the trend towards market expansion, higher drug volumes must be transported further, necessitating the use of logistics coordination on a global scale. As distribution needs increase, the knock-on effect of state-enforced cost-containment strategies are reducing already tight margins, forcing many stakeholders to change their strategy.
Manufacturers are looking to gain greater control over the drug supply chain, to safeguard it against counterfeit entry, but also to regulate drug supply and therefore limit diversion. The most progressive events have occurred in the UK, where Pfizer has implemented direct to pharmacy distribution, with other companies likely to follow suit.
Competitive pressures have and will continue to drive consolidation along the supply chain, with vertical integration providing a means of extending control and limiting margin loss. A relaxation in pharmacy laws in Europe will lead to an increase of chains, while wholesaler-pharmacy and manufacturer-pharmacy combinations are becoming common.Gain an understanding of the pharmaceutical supply chain in the US and Europe, and who the key players are.Become aware of new issues in the distribution industry, and how they influence the major stakeholders.Gain an insight into current trends in distribution, and how they are likely to change going forward. |
|
| SLE is a chronic, life-long and potentially fatal autoimmune disease characterized by multiple system distress and unpredictable flares. Therapy is largely off-label and a huge demand exists for new SLE therapies because of the potential for serious side effects from drugs currently used in the management of the disease.Assessment of patient size across the seven major and additional emerging markets, including split by sex and race where available.Commercial and clinical assessment of the therapies in the developmental pipeline.Opinion of the market potential from a range of physicians involved in SLE treatment and research.An update of the challenges facing the design of clinical trialsThe SLE market will enter an era of targeted therapies thanks to greater understanding of disease mechanisms. Rituxan/MabThera (rituximab) is the most advanced pipeline candidate and will be the first product approved in the last 40 years. It is already used off-label in severe, refractory patients, with maximum estimated sales $650m.
Caution must be maintained as products for SLE have been prone to failure, as evidenced by La Jolla's Riquent, Genelabs's Prestara and Apreva's CellCept. Companies must learn from past mistakes by improving SLE clinical trial design and communicating fully with regulatory agencies.
The SLE patient population in the seven major markets is estimated to be 430,000 in 2008. However, the combined SLE patient population in Mexico, China and India could be a minimum of 0.9 billion in 2008, suggesting pharmaceutical companies should seek product approval in emerging markets.Understand the key opportunities and threats in the SLE marketAssess the commercial potential of the products in the late-stage pipelineGain insight into opinion leaders' thoughts on the challenges facing the SLE market |
|
| Today, pharma companies face growing competition from generics and me-too drugs, combined with increasingly tough P&R, a clamp down on healthcare spending, and the need to treat patients for longer due to the aging population. These factors threaten both current and future revenues prompting Pharma to adopt a range of corporate strategies to respond to the changing market dynamics.Review of key external factors impacting Pharma and shaping their strategiesAnalysis of steps undertaken by pharma companies to achieve cost saving and improve efficiencyAssessment of corporate strategies employed by drug developers to generate new revenue growthFewer drugs are gaining FDA approval year-on-year, primarily due to increasing pressure the pharmaceutical industry is facing over drug safety, fueled by several recent high-profile drug withdrawals and black box warnings. Compounded with the recent expansion of the FDA's safety powers, this will have a negative impact on Pharma's profitability.
The pharmaceutical industry is facing increasingly cost-conscious times, with a declining ROI and numerous blockbuster products facing imminent generic competition. This is exacerbated by the increasing cost of licensing and M&A deals, and a harshening P&R environment.
A key trend in 2007 has been the vast number of job cuts across Big Pharma in an effort to cut costs, in response to disappointing financial results driven by patent expiries of key products and resulting generic erosion. Price pressure and low reimbursement rates, which are impacting company revenues, are set to continue in 2008.Identify the key trends that are impacting the industry in 2007, going forward in 2008 and beyondUnderstand what strategic steps pharma companies are making to maintain their profitability by cutting costsGain insight into how Pharma are capturing new opportunities to sustain historic growth rates |
|
| Bone metastases are a complication of some advanced cancers including cancers of the breast, lung, prostate, kidney and thyroid. The incidence of bone metastases across these tumor types in the seven major markets is forecasted to total 225,174 in 2008. While treatment with bisphosphonates reduces the risk of skeletal complications, they do not improve survival in the majority of patients.Overview of bone metastases epidemiology, which is currently unknown, disease mechanisms, complications and diagnosisCurrent treatment options and identification of unmet needs in bone metastasesResearch and analysis of the bone metastases pipeline with clinical and commercial assessment of late-phase candidatesStakeholder opinions based on qualitative interviews with key opinion leaders from the US and EUCurrent bisphosphonate therapy reduces the risk of skeletal complications such as fractures and bone pain but as yet do not offer a survival advantage in the majority of patients. More efficacious agents that improve survival and enhance the quality of life of advanced cancer patients with bone metastases would be highly welcome.
Survival of bone metastases patients varies according to primary cancer type and largely remains unchanged with current treatment. In light of this, an emerging opportunity is the potential of bisphosphonate therapy to prevent bone metastases when given in early stage cancer patients, for which trials are ongoing.
Approaching patent expiries for Bondronat and Zometa and the subsequent availability of cheaper generic versions may raise the barrier to uptake of more novel but costly emerging agents such as denosumab. However, significant opportunity exists to succeed in the bone metastases market if newer agents can demonstrate superior efficacy and/or safety.Gain an insight into the epidemiology trends as the true incidence of bone metastases is currently unknownIdentify the limitations of current bone metastases therapy and consider the remaining unmet needsAcquire a detailed appreciation and impartial perspective of the bone metastases pipeline and identify the key products in late-phase development |
|
| Latin American countries have attracted a lot of attention recently. With their economies currently stable, their geographic location and low-cost is ideal for investors. In addition, having such a high and varied population eases recruitment for clinical trials, and the demographics show there is a very high need for pharmaceuticals.Overview of the key trends driving the pharmaceutical market growthAnalysis of key healthcare system characteristics impacting the pharmaceutical marketAnalysis of pharmaceutical market dynamics in Argentina and MexicoOverview of key pharmaceutical players in Argentina and MexicoAlthough both the Argentinean and the Mexican markets have been growing, their growth is attributed to different reasons. The Argentinean pharmaceutical market has been growing mainly based on growing sales volume, while growth of the Mexican market is mainly driven by growing prices.
The Mexican market is dominated by foreign companies with few domestic players. The Argentinean market is dominated by domestic branded generics firms, due to the economic crisis which led to many foreign companies to sell their plants in Argentina, thus allowing the domestic firms to gain over their market share.
Sales of pharmaceutical categories in both countries are very similar to the West thus opening growth opportunities for foreign companies. However, sales of oncology drugs are low in both countries; and Mexico has higher sales of anti-infective drugs indicating that these markets still have scope for further development and growth.Identify the healthcare needs in Argentina and MexicoUnderstand the barriers and drivers for entering these marketsGain insight into pharmaceutical dynamics of Argentina and Mexico |
|
| Technology markets are changing fast. This brief identifies and tracks the key forces shaping your business. Datamonitor's healthcare technology analyst will outline the main business priorities in your market, explain which trends will have the biggest impact and highlight technologies that healthcare organizations are most likely to invest in this year.An overview of challenges facing healthcare organizations in 2008Datamonitor's view of the technology priorities of providers and payersStrategies to help vendors in the healthcare technology marketDatamonitor believes improving quality of care will be a top of mind priority for healthcare organizations in 2008
Providers will continue to invest in clinical and administrative applications
Interoperable solutions will be more important than ever in healthcareLearn about the top trends in healthcare in 2008Gain insight into the technology areas healthcare organizations are investing inIdentify strategies for expanding business opportunities in healthcare |
|
| Existing sales and marketing models are considered unsustainable. Pharma has been slow to adapt and take advantage of the marketing opportunities offered by the internet. Meanwhile customers are increasingly using the web to source information. Pharma needs to evolve and engage with their customers online, or risk being left behind.Overview of the current challenges facing existing sales and marketing models.A review of online activities of physicians and patients and how Pharma companies are currently targeting customers.Analysis of Pharma companies current online strategies supported by case study analysis.Review and recommendations of new media strategies Pharma could potentially consider.Rising healthcare cost, P&R controls public skepticism of Pharma companies and legal issues have made the current sales and marketing model unsustainable, they need for specialized sales forces and increased use of the internet as a customer information resource.
Increased access to the internet has led a growth in physician and patient websites. Pharma companies need to move forward from the traditional company website and actively engage with its customers.
The rise in social media, blogging forums opens up potential opportunities for Pharma marketers, also there are a variety of mediums such as podcasts and live video detailing which are currently underutilized.Understand the opportunities and threats facing Pharma companies existing sales and marketing models.Provides an overview of Pharma's current online strategies and how they are failing to make an impact.Identification of new media opportunities that Pharma could undertake to engage with their target audiences online. |
|
| This Datamonitor study examines top business challenges, IT budget outlook and spending priorities among healthcare providers in the US, Canada, France, Germany, Spain and the UK. It is based on the results of Datamonitor's Business Trends primary research, conducted in Q3 and Q4 of 2007 with a total of 150 hospitals.150 healthcare provider interviewsGeographic coverage includes the US, Canada, France, Germany, Spain and the UK.North American hospitals surveyed are more likely to invest in clinical applications in the next 6 months than European hospital respondents.
PACS, Telehealth and EHRs will continue to be important investment areas for hospitals in the future.
As hospitals look to increase efficiencies and customer satisfaction, vendor solutions that are able to do both will be preferred.Effectively map IT solutions to address healthcare business pain pointsGain firsthand insight on spending priorities and budget outlooksTarget healthcare customers more effectively |
|
| Electronic health records (EHRs) will be the cornerstone of healthcare technology. The design, selection and implementation of EHRs, therefore, will be extremely important for healthcare institutions.Identifies the key forces driving the adoption of EHRsAnalyzes opportunities in the global EHR marketDraws comparisons between EHRs and technologies in other industriesCost is the most significant, but not the only, barrier to adoption.
Datamonitor expects the global market for EHRs from 2007-2012 will grow at a five-year compound annual growth rate of 23.8%.
As EHRs become more advanced, they will require solutions from multiple vendors.Align product messaging with what will resonate best with healthcare organizationsIdentify strategies that will increase EHR adoptionUnderstand the technology trends that are shaping the future of EHRs |
|
